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Abstract 
 
Spinobulbar muscular atrophy (SBMA), or Kennedy’s disease, is an inherited 
neuromuscular disorder caused by a polyglutamine (polyQ) tract expansion in the androgen 
receptor (AR). This mutation initiates misfolding and aggregation of AR, eliciting toxicity in 
motor neurons, progressive weakness, and muscle atrophy. PolyQ expansion also compromises 
the transactivation function of AR in response to androgens, resulting in androgen insensitivity. 
Although considerable progress has been made in characterizing molecular consequences of the 
polyQ mutation in SBMA, many aspects of pathogenesis, and in particular the cellular processes 
that modify disease development, remain incompletely understood. 
Based on previous work suggesting a pathogenic role of autophagy in SBMA, I use 
cellular and mouse models to delineate the state of autophagy in SBMA. I show that autophagy 
is induced in SBMA cells and diseased tissues, and that this is due to depressed mTOR activity. 
These changes correlate with activity of the transcription factors TFEB and ZKSCAN3, which 
coordinate expression of autophagy-related genes in SBMA mice and human patients. 
Furthermore, these alterations in the regulators of autophagy lead to enhanced responsiveness to 
stimulation by nutrient deprivation and exercise. These results indicate that dysregulated 
transcriptional programming promotes induction of autophagy in SBMA and provide evidence 
for targeting autophagy for therapeutic inhibition. 
 ix 
 Given the previously established role of small ubiquitin-like modifier (SUMO) on AR 
function, I characterize a novel knock-in mouse model of SBMA to address the influence of 
SUMO on SBMA pathogenesis. We introduce mutations that prevent SUMOylation of polyQ 
AR (AR113Q-KRKR) and demonstrate that, despite unaltered androgen insensitivity and 
neuromuscular pathology, AR113Q-KRKR mice display a striking extension of lifespan and 
recovery of exercise tolerance. Complementary expression analysis of the non-SUMOylatable 
polyQ AR reveals substantial expansion of the receptor’s transactivation activity. These findings 
suggest that abrogating SUMO modification of polyQ AR mediates amelioration of the SBMA 
phenotype, in part by improving skeletal muscle physiology. Additionally, these studies not only 
reveal new insights in the comparative roles of polyQ AR toxicity versus loss of function in 
affected tissues, but they also establish the benefits of enhancing AR function in SBMA for 
therapeutic design. 
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Chapter 1 
 
Introduction 
 
1.1  Spinobulbar muscular atrophy (SBMA) 
 
1.1.1 Clinical features, genetics, and pathogenesis 
Spinobulbar muscular atrophy (SBMA) is an inherited, slowly progressive degenerative 
disease of lower motor neurons and skeletal muscle. Also known as Kennedy’s disease, after the 
eponymous neurologist William R. Kennedy first described the principal features in 1968, 
SBMA is characterized clinically by progressive atrophy and weakening of the bulbar and limb 
musculature [1]. Common symptoms include dysarthria, dysphagia, tremor, and gait disturbances 
[2, 3]. The muscular clinicopathology of SBMA patients is characteristic of lower motor neuron 
disease with bulk atrophy, flaccid paralysis, hyporeflexia, and fasciculations [4]. Evidence of 
primary myopathy also exists with painful cramps, weakness, and elevated serum creatine kinase 
(CK) levels [5]. In addition, SBMA patients commonly exhibit androgen insensitivity, with 
symptoms including gynecomastia, testicular atrophy, and oligospermia [6]. On histopathologic 
examination, by end stage disease there is marked anterior horn cell loss in both brainstem and 
spinal cord, and dorsal root ganglia also exhibit a decreased number of sensory neurons [7-9]. 
Skeletal muscle biopsies show angulated atrophic fibers and fiber type grouping suggestive of 
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denervation [10]. The prevalence of SBMA is estimated to be at approximately 1 in 40,000, with 
a proportionally greater number of cases in Japan and Finland, but many patients are likely 
misdiagnosed due to similar clinical features to amyotrophic lateral sclerosis and other, more 
common motor neuron diseases [11, 12]. There is currently no established or effective treatment 
for SBMA. 
The occurrence of SBMA through multiple generations of patient families suggested a 
genetic basis of disease, and the segregation pattern initially indicated an X-linked recessive 
mode of inheritance [1]. Subsequently, La Spada et al. were the first to identify the causative 
mutation in 1991, which consists of an expansion of a CAG repeat tract in exon 1 of the 
androgen receptor (Ar) gene located on the long arm of the X chromosome (Xq11-12) [13]. Of 
the nine polyglutamine diseases, which include Huntington’s disease, dentatorubropallidoluysian 
atrophy (DRPLA), and six sub-types of spinocerebellar ataxia (SCA 1, 2, 3, 6, 7, and 17), the 
causal link between polyglutamine tract expansion and neurodegenerative disease was first 
established in SBMA. As is characteristic of trinucleotide repeat disorders, SBMA exhibits both 
CAG-repeat instability and anticipation, or an inverse relationship between tract length versus 
age of onset and severity of disease [14-19].  
Unlike the other polyglutamine diseases, which are inherited in an autosomal dominant 
fashion and are fully penetrant, SBMA only manifests in male patients while exhibiting little to 
no disease phenotype in females [14, 20-23]. Although the diminution in disease penetrance in 
females was initially attributed to lyonization, the identification of subclinical and asymptomatic 
females homozygous for the mutant allele made this explanation unlikely [19, 22, 24, 25]. 
Furthermore, although the AR is widely expressed in multiple tissue types, SBMA pathology 
paradoxically remains isolated within a few distinct cell populations. These observations 
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illustrate two key features of SBMA pathogenesis – hormone dependency and selective cellular 
vulnerability – which will be further discussed in later sections. 
The causative mutation for SBMA resides in the androgen receptor protein, a Group I 
steroid hormone nuclear receptor that contains three principal domains: an N-terminal domain 
(NTD), DNA-binding domain (DBD), and ligand-binding domain (LBD), with a small hinge 
interregion between the DBD and LBD containing a bipartite nuclear localization sequence [26-
29]. The DBD and LBD orchestrate the principle functions of the AR as a steroid hormone 
receptor. Unbound by ligand, the inactive AR resides in the cytosol bound to chaperone proteins. 
Upon binding of the LBD by cognate androgens testosterone and dihydrotestosterone (DHT), the 
AR assembly with the chaperone machinery becomes much more dynamic, the AR 
homodimerizes and the AR-ligand complex translocates to the nucleus to bind DNA via the 
DBD, whereupon modulation of genes containing an androgen response element occurs. This 
mechanism of action allows androgenic hormones to exert masculinizing and trophic effects in 
target tissues. 
Further control of these functionalities is accomplished through numerous regulatory 
elements including short tandem amino acid repeats and sites for post-translational modification. 
One such element consists of a CAG repeat stretch that encodes a glutamine (Q) tract that is 
associated with length-dependent modification of AR function. The polyglutamine tract is highly 
polymorphic and ranges between 8 and 35 repeats in the general population [30]. Shorter CAG 
tracts correlate with increased ligand-mediated activation of the AR, while longer tracts, even 
within the normal range, appear to depress AR activity [31-37]. CAG tracts above a critical 
threshold length of 38 glutamines result in SBMA, as these expanded polyglutamine stretches 
promote unfolding of the AR and provide large polar surfaces essential for driving the interaction 
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and aggregation of AR monomers [38, 39]. Surviving lower motor neurons and scrotal skin 
biopsies from SBMA patients consequently demonstrate nuclear inclusions of aggregated AR 
with the appropriate histochemical staining [8, 40-42]. Importantly, although AR function is 
negatively correlated with CAG tract length, a partial loss of function mediated by CAG 
expansion fails to provide adequate explanation for both the androgen insensitivity and 
neuromuscular pathology seen clinically in SBMA [32, 43-47]. Rather, pathogenic CAG 
expansion is presumed to confer an additional toxic gain of function to the AR, since patients 
with androgen insensitivity syndrome stemming from AR loss of function mutations do not 
exhibit the neuromuscular pathology of SBMA [48].  
 
1.1.2 Regulation of AR function  
Post-translational modifications coordinate additional alterations of AR function. 
Phosphorylation occurs both in the presence and absence of androgen and directs multiple 
effects, including regulation of AR conformational changes, localization, and turnover, 
potentiation of ligand responsiveness and transcriptional activity, and protein-protein interactions 
[49-54]. Phosphorylation is upregulated in prostate cancer and correlates with increased 
morbidity and mortality, while negatively modifying toxicity in SBMA [52, 55, 56]. AR 
acetylation regulates cofactor association, transcriptional activity, and prostate cancer cell growth 
and survival [57-62]. Modification by small ubiquitin-like modifier (SUMO) occurs at two lysine 
residues within consensus SUMOylation motifs in the NTD, negatively regulates AR 
transcriptional activity, and negatively modulates both prostate cancer proliferation and 
progression and SBMA cytopathology (discussed further below) [63-69]. Ubiquitination 
mediates AR degradation through the ubiquitin-proteasome system or augments AR 
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transactivation, depending on the biological context and E3 ligase involved [70-74]. In SBMA, 
chaperone-enhanced ubiquitination of the AR increases AR degradation and ameliorates disease 
[75].  
In addition, the NTD and LBD contain several transcriptional activation function (AF) 
domains. The NTD contains AF-1, which encompasses residues 142-485 and is necessary for 
full ligand-dependent transactivation, and AF-5, which encompasses residues 351-528 and is 
sufficient to act as a ligand-independent, constitutively active transcriptional activator [76-79]. 
AF-1 mediates a ligand-dependent intramolecular interaction of the NTD with the C-terminus of 
the AR via consensus FxxLF/WxxLF motifs (F = phenylalanine, W = tryptophan, x = any amino 
acid), and this interaction is necessary for AR transactivation in vivo [80-84]. The LBD contains 
AF-2, which is required for ligand-dependent AR activation [85, 86]. Within AF-2 are binding 
sites that recognize leucine-rich motifs with the conserved sequence LxxLL (L = leucine, x = any 
amino acid) that mediate interactions with AR coactivators [87, 88]. These native functionalities 
are not only essential for normal AR function but also SBMA pathogenesis, as disruption of 
these domains significantly attenuates AR aggregation and toxicity [89, 90]. 
 
1.1.3 Ligand-dependent toxicity 
As indicated previously, a unique feature of SBMA is the initiation of pathogenesis by 
androgens, the endogenous ligands of AR. Ligand dependency accounts for the predominant 
incidence of SBMA in male patients and paucity of disease even in female homozygotes, since 
females harbor much lower levels of circulating androgens. Furthermore, since key pathogenic 
events in both SBMA and other proteinopathies are unfolding and aggregation of mutant 
proteins, and since aspects of these events are concentration-dependent, it follows that 
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compartmentalization of the polyQ AR in the nucleus, mediated by ligand-dependent nuclear 
translocation, is a critical step in SBMA [91-93]. 
Among the cellular models of SBMA, the dependence of disease on ligand is well 
established. In the mouse-rat hybrid glioma-neuroblastoma line NG108-15, in which AR22Q and 
AR52Q are stably transfected, the androgen-dependent proliferation present in cells expressing 
wild type AR is abrogated in cells expressing an expanded Q-tract AR [94]. Similarly, transient 
expression of AR constructs in simian COS-7 cells demonstrates ligand-dependent toxicity and 
aggregation [95]. Treatment with antiandrogens in the COS-7 model and deletion of the LBD 
abrogate these effects, and antiandrogens rescue pathologic aggregation of the mutant AR in 
Neuro2a cells [95, 96]. These findings demonstrate the essential role of ligand binding for fully 
reproducing SBMA cytopathology.  Ligand dependent toxicity is also demonstrable in a PC12 
cell model stably transfected with an expanded Q-tract full length AR under the control of a 
tetracycline-inducible promoter [97]. The glutamine-length appearance of morphologically 
visible nuclear inclusions, high molecular weight aggregates on Western blot, and cytotoxicity 
are produced only in the presence of androgen or synthetic androgen analogs. Notably, nuclear 
translocation per se is not sufficient to initiate pathogenesis, suggesting that ligand binding itself 
initiates additional conformational changes and cellular processes necessary for full development 
of disease [98]. 
In vivo, the recapitulation of disease in a ligand-dependent manner occurs in both mice 
(males compared to females) and Drosophila (DHT treatment over vehicle) [91-93, 99-101]. 
Importantly, the gender limitation in mice occurs only in models expressing a full length 
androgen receptor, indicating that the truncated version of polyQ AR, which does not contain the 
LBD, lacks features of the protein critical for full disease iteration. Additionally, symptoms and 
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pathology comparable to the male phenotype in mice can manifest in females when treated with 
androgen [91, 101]. Furthermore, prevention of polyQ AR nuclear translocation and amelioration 
of disease occurs with mutation of the nuclear localization signal or surgical and pharmacologic 
castration [91, 98, 100, 102]. Together, these data in vivo clearly implicate the essential role of 
androgens in SBMA and inform efforts to assess androgen-targeted therapy in human clinical 
trails. 
 
1.1.4 Partial loss of AR function 
One proposed explanation for the loss of AR function phenotype in SBMA, manifested in 
human patients as androgen insensitivity, is lower expression levels of the expanded Q-tract AR 
compared to wild type AR. This observation is documented in both SH SY-5Y and MN-1 cell 
models as well as in vivo [47, 103-105]. Additionally, expansion of the glutamine tract itself 
intrinsically confers diminution of AR transactivation, as demonstrated by expression assays 
comparing WT and expanded Q-tract AR in MN-1 cells and AR110Q YAC transgenic mice [47, 
106]. Expansion of the glutamine tract also accelerates AR turnover, thereby yielding further 
decrement in AR function [47]. Notably, testicular abnormalities, including disruption of germ 
cell maturation in AR113Q knock-in male mice, reveal toxic effects of the mutant protein, 
suggesting that phenotypic features such as diminished male fertility may be caused by a mixture 
of both loss and gain of function conferred by the expanded glutamine tract [107]. 
 
1.1.5 Transcriptional dysregulation 
 In addition to negative effects on the intrinsic transactivational capacity of the AR, 
aberrant cofactor interaction has been posited as a mechanism responsible for the toxic gain of 
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function of the expanded Q-tract AR. One key observation in MN-1 cells, mouse, and 
Drosophila models of SBMA is the co-localization of transcription factors, including CREB 
binding protein (CBP), in nuclear inclusions of the mutant AR, suggesting that cytotoxicity 
stems in part from abnormal interaction with and sequestration of transcription factors leading to 
dysregulation of gene expression, including that of vascular endothelial growth factor (VEGF) 
and transforming growth factor β (TGFβ) receptor type II [93, 108-111]. Analogously, these 
pathologic changes are shown to occur in other polyglutamine diseases [112, 113]. Interestingly, 
CBP and several other inclusion interactors also contain polyglutamine tracts, which may 
facilitate AR-cofactor association.  
It has therefore been hypothesized that accumulation of these factors and other critical 
regulators in nuclear inclusions results in a depletion of their availability, thereby compromising 
their functions in transcription. In line with this model of pathogenesis, treatment of cell and 
animal models with HDAC inhibitors and overexpression of CBP in a Drosophila model of 
polyglutamine disease significantly improves transcriptional aberrancies and rescues cell death in 
vitro, ommatidial degeneration in Drosophila, and improves both survival and motor 
performance in SBMA mice [108, 114-116].  
 
1.1.6 AR and proteotoxicity 
Neuronal intranuclear inclusions (NII), defined as proteinaceous aggregates visible on 
histopathology with the appropriate staining, are a pathognomonic feature of SBMA, contain at 
least a portion of the polyQ AR, and are found in lower motor neurons and scrotal skin cells of 
SBMA patients [8, 40-42]. These inclusions are similar to those identified in other polyQ 
disorders and their role in disease pathogenesis is similarly controversial. In model systems of 
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SBMA, as in other polyQ diseases, these large nuclear inclusions do not always correlate with 
cell death. Rather, pathology is better correlated with the occurrence of microaggregates, which, 
in contrast to inclusions that are defined histopathologically, are soluble intermediates of 
aggregated and unfolded mutant proteins that are isolated biochemically [117-120]. Specifically, 
glutamine-length dependent toxicity can be demonstrated in the SH SY-5Y model of SBMA 
without aggregate formation [103]. Moreover, toxicity correlates with microaggregates in the 
inducible PC12 cell model of SBMA as well as Sf9 cells and Drosophila [97, 121].  
Additional studies further dissociate toxicity from AR inclusions. Treatment of HEK293, 
PC12, and Drosophila models of SBMA with the compound B2 promote inclusion formation 
and reduce toxicity [122]. In HEK293 and MN-1 cells, expansion of the AR glutamine tract 
promotes its incorporation in the formation of aggresomes, which are large juxtanuclear 
structures similar to intranuclear inclusions [123]. Aggresomes and inclusions may represent a 
cellular adaptive response to mutant AR and other aggregated proteins, since their formation 
correlates with cell survival and their disruption exacerbates cytotoxicity [124]. These results 
lend further support to the notion that aggregates are end-stage, protective structures rather than 
the primary toxic entity. 
 The sole detection of AR amino-terminal epitopes within nuclear inclusions from SBMA 
patient tissue suggested that these aggregates are composed of a proteolytic byproduct of the AR 
protein that includes the expanded glutamine tract [40, 41]. Pathogenic proteolysis of the AR 
occurs in a caspase-dependent manner in vitro, in line with proteolytic processing seen in other 
polyglutamine disease models [44, 125-136]. Although expression of truncated polyQ AR 
fragments in cell and Drosophila models confers toxicity in a glutamine-length dependent 
manner, expression of amino-terminal truncated fragments in mice causes toxicity that does not 
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exhibit the gender delimitation or cell-type specificity of SBMA [109, 137, 138]. Taken together, 
these studies indicate that, although protein cleavage is likely a component of the disease process 
that generates a toxic protein fragment, model systems based on expression of these fragments 
do not reproduce essential aspects of the SBMA phenotype.  
 
1.1.7 Chaperones and AR proteostasis 
 Heat shock proteins (HSP) are essential regulators of protein folding, function, and 
stability. For the AR, the heat shock protein 90 (Hsp90)-based chaperone machinery serves to 
modulate ligand affinity, ligand-dependent conformational changes, and nuclear trafficking 
following ligand binding. In this machinery, association with Hsp90 stabilizes the AR, whereas 
proteasomal degradation of the unfolded receptor is regulated by Hsp70 and its co-chaperones 
through the recruitment of chaperone-dependent E3 ubiqutin ligases including CHIP (C-terminal 
Hsp70-interacting protein) [72-74, 139-143]. Multiple studies indicate the involvement of these 
chaperones in SBMA pathogenesis. Components of the Hsp70/90 machinery co-localize in 
mutant AR aggregates, suggesting abnormal seqestration of these chaperones and raising the 
possibility of dysregulation of chaperone-mediated proteostasis [109, 144]. Conversely, 
overexpression of Hsp70 or pharmacological inhibition of Hsp90 increases AR degradation and 
amelioriates disease phenotype in cellular and mouse models of SBMA, and similar beneficial 
effects in SBMA mice are observed following overexpression of CHIP [75, 145-147]. 
Administration of 17-diethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) and 17-
N-allylamino-17-demethoxygeldanamycin (17-AAG), which are derivatives of geldanamycin 
and inhibitors of Hsp90, promote degradation of the AR and improve motor performance in 
AR97Q transgenic mice [148, 149]. Together, these studies establish that inhibition of Hsp90 or 
 11 
activation of Hsp70-dependent ubiquitination are promising therapeutic targets for trial in SBMA 
patients. 
 
1.1.8 Pathways downstream of AR 
In addition to causing transcriptional and proteostatic dysregulation, the toxic gain of 
function conferred by the expanded glutamine tract disrupts a large number of downstream 
pathways that are critical for cell survival (Fig. 1.1). Hormone and glutamine length dependent 
changes in RNA processing have been demonstrated in SBMA knock-in mice, indicating that 
both transcriptional and post-transcriptional regulation of gene expression is altered in disease 
[150]. Additionally, multiple cytosolic targets of toxicity have been identified. MN-1 cells 
expressing AR65Q demonstrate marked mitochondrial pathology, increased activation of the 
intrinsic apoptosis pathway, and dysregulation of nuclear-mediated mitochondrial gene 
expression through PGC-1 suppression, while antioxidant treatments rescue toxicity [136, 151]. 
These studies suggest that expansion of the AR glutamine tract promotes mitochondrial 
dysfunction and provides a direct causal link between transcriptional aberrance and 
mitochondrial pathology.   
Additionally, the unfolded protein response is significantly upregulated in SBMA cell 
models and in AR113Q knock-in mice, and genetic deletion of the ER stress-dependent 
transcription factor CHOP (C/EBP homologous protein) exacerbates disease phenotype, thereby 
implicating a role of ER stress in SBMA [152, 153]. The polyQ AR has also been shown to 
compromise retrograde axonal transport, an effect that may contribute to lower motor neuron 
degeneration [154-157]. While cell-autonomous toxicity within vulnerable cell populations may 
be mediated by abnormal protein interactions (see above), there is also evidence that toxic effects  
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Figure 1. Multiple cellular pathways altered by polyglutamine expansion in AR. 
Expansion of the polyglutamine tract in the NTD of the androgen receptor (denoted by series of 
Qs) beyond 38 CAG repeats promotes AR unfolding and is necessary but not sufficient for 
development of SBMA. (a) Binding of polyQ AR to cognate ligands testosterone and DHT 
drives the conformational changes and nuclear localization of the mutant protein required for full 
pathogenesis. (b) Reduction of transactivation function leads to disruption of androgen-
responsive gene expression and (c) transcriptional dysregulation, which in turn contribute to the 
phenotype of androgen insensitivity in SBMA patients. (d) Proteolysis of the polyQ AR, which 
may be caspase-mediated, generates toxic, N-terminal fragments of the mutant protein that 
ultimately oligomerize and aggregate in nuclear inclusions. (e) These inclusions contain 
accumulations of transcriptional cofactors (such as CBP), molecular chaperones (such as 
Hsp70/90 complexes), and splicing machinery, the depletions of which further disrupt vital (c) 
transcriptional and proteostatic processes and (f) RNA splicing. Selectively vulnerable cell 
populations in SBMA experience additional toxic insults, including (g) mitochondrial pathology, 
(h) ER stress, and (i) disruption of retrograde axonal transport. AR, androgen receptor; polyQ, 
polyglutamine; ARE, androgen response element; VEGF, vascular endothelial growth factor; 
TGFβR-II, transforming growth factor β receptor type II; CBP, CREB binding protein; snRNP, 
small nuclear ribonucleoprotein. 
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arising in skeletal muscle initiate non-cell-autonomous degeneration of lower motor neurons, 
perhaps by impairing trophic support [52, 101, 158-161]. Taken together, these studies indicate 
that multiple downstream pathways are disrupted by the polyQ AR. As no single pathway has 
emerged as a critical mediator of pathogenesis, we suggest that therapeutic strategies targeting 
the mutant protein may be most effective in modifying the course of disease.  
 
1.1.9 Therapeutic interventions and clinical trials 
 The understanding of disease mechanisms gleaned from cell and animal models have 
provided the basis for several clinical trials to date. To address the ligand-dependency of SBMA, 
administration of leuprorelin acetate, which is a partial agonist of gonadotropin releasing 
hormone and a potent suppressor of testosterone release, rescued disease in AR97Q mice [91, 
102]. These results were translated into a phase 2 trial for the use of leuprorelin in SBMA 
patients [162, 163]. Leuprorelin treatment for 48 weeks did not produce significant improvement 
in the primary outcome measures of Revised ALS Functional Rating Scale (ALSFRS-R) score 
and serum CK level. Several secondary outcomes showed significant rescue, including measures 
of cricopharyngeal function and nuclear inclusions on scrotal skin biopsy.  Furthermore, in an 
open label follow-up, all of these measures except serum CK saw significant improvement after 
96 weeks.  
These encouraging findings were followed by the phase 3 trial known as the Japan 
SBMA Interventional Trial for TAP-144-SR (JASMITT). In this larger study, the leuprorelin 
group saw no significant recovery of cricopharyngeal function or ALSFRS-R scores, although 
there were significant improvements in some secondary measures, including reduced 
polyglutamine positive cells in scrotal skin biopsies and serum CK levels. In a separate trial, 
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administration of dutasteride, which inhibits 5α-reductase and thus enzymatic conversion of 
testosterone to the more potent androgen DHT, similarly found no significant improvement in 
primary endpoints [164].  
The equivocal findings of androgen-targeted therapies in humans highlight difficulties in 
treating a slowly progressive disease where clinical severity may vary depending on CAG repeat 
length or other genetic and environmental factors. Though anti-androgens displayed promise for 
slowing disease progression, these trials also raised the possibility that intervention early in the 
disease course may be most effective. In these studies, the average disease duration in trial 
patients at the time of enrollment ranged from 10.8 to 13.3 years [162-164]. Whether patients 
earlier in the course of disease are more responsive to therapeutic intervention is an important 
unanswered question. This work also revealed the urgent need for further studies to better 
understand the natural history of SBMA and to develop sensitive surrogate markers that will 
facilitate long term follow-up in future trials.  
  An important, unresolved question for SBMA patients is whether exercise is beneficial. 
Currently, there is one two-year clinical trial underway to assess the efficacy of functional 
exercise and stretching (Trial Number 11-N-0171; NCT01369901). The results of this study will 
be informative about the applicability of exercise to SBMA therapy, as the benefit or harm of 
exercise is not well established in this disease or other neuromuscular disorders [165-168]. 
Future clinical trial candidates include ASC-J9, a disruptor of AR-coregulator interactions and 
promoter of AR/aggregate clearance, and insulin-like growth factor 1 (IGF-1), both of which 
have been shown to improve disease phenotype in vitro and in vivo [158, 169]. Both agents 
require further study in preclinical models before advancing to clinical trial. 
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 The number of pathogenic mechanisms implicated in SBMA is demonstrative of the 
complexity inherent in this polyglutamine disorder and presents many challenges to solving 
critical scientific and therapeutic questions. Despite the pathophysiological intricacy of SBMA, it 
is important to note that the variety of cellular processes disrupted share a common initiatory 
stimulus in the form of the polyQ AR. It therefore follows that pursuing and optimizing 
therapeutic strategies targeting the polyQ AR in particular would prove most beneficial in 
ameliorating disease vis-à-vis targeting the multiple downstream sequelae. In particular, the 
clinical shortcomings to date of using ligand-based therapies may be overcome if used in 
combination with other strategies, such as chaperone-directed, to potentiate their AR-targeted 
effects. Additionally, recent evidence suggests that the polyQ AR may be an autophagic 
substrate when it is localized to the cytoplasm [98, 170], but the extent to which autophagy 
activators will alleviate disease in vivo remains unclear [152]. 
Furthermore, traditional clinical measures used to assess disease status in other 
neuromuscular diseases suffer from inadequate applicability in SBMA trials due to marked 
variability of these measures among SBMA patients, poor sensitivity, and a dearth of established 
clinical reliability. Future trials would most benefit from primary endpoints defined by reliable 
outcome measures that more accurately reflect disease progression, patient self-assessments, and 
therapeutic efficacy. Trial design might also benefit from longer duration, earlier initiation of 
interventions and greater enrollment of patients. These parameters, unfortunately, are limited by 
the small patient population available for this rare disorder and the poor diagnostic sensitivity for 
SBMA. Subsequent research following promising leads into overcoming these clinical and 
therapeutic challenges and further disentangling SBMA pathogenesis will improve quality of 
care and address disease mechanisms common to SBMA and other neurodegenerative disorders.  
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1.2 Macroautophagy 
 
1.2.1 The autophagic pathway 
As the unfolded mutant AR protein is the proximal mediator of toxicity in SBMA, 
pathways that regulate cellular proteostasis have attracted considerable attention in the field. 
Among these pathways is macroautophagy (hereafter referred to as autophagy), a highly 
conserved catabolic process in which misfolded or dysfunctional proteins and organelles in the 
cytoplasm are sequestered and targeted for bulk degradation. Initially characterized in yeast, the 
process of autophagy in eukaryotes is executed by autophagy-related gene (Atg) proteins in an 
adaptive, protective response to stresses including nutrient deprivation, metabolic stress, 
infection, and cancer [171]. First, an autophagic initiation complex directs the formation of a 
double-membraned structure known as a phagophore at the phagophore assembly site [172]. The 
core machinery of this initiation complex includes Atg1/unc-51 like kinase (ULK), Atg12, 
Atg8/microtubule-associated light chain 3 (LC3), class III phosphatidylinositol 3-kinase (PI3K) 
complex, and Atg9/mAtg9 (terms listed are yeast orthologue/mammalian orthologue, 
respectively) [173]. The phagophore extends to envelope cytoplasmic cargo and closes off to 
form a mature autophagosome, which is then trafficked to and fuses with the lysosome and 
thereby enables degradation of intraluminal contents [174].  
 
1.2.2 Regulatory mechanisms of autophagy 
Regulation of autophagy is achieved through a variety of signaling mechanisms, 
including the mammalian target of rapamycin (mTOR) pathway, which acts as a nutrient sensor 
and whose phosphorylation status and activation repress autophagy [175]. Autophagy is also 
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regulated by Beclin-1, which binds the PI3K complex involved in autophagic induction to direct 
conversion of PIP2 to PIP3 and thereby activate autophagy [176, 177]. Additional regulation of 
autophagy is performed by the recently characterized transcription factor EB (TFEB), which 
functions as a master regulator of autophagy and lysosomal biogenesis by directing the 
transcription of hundreds of autophagy- and lysosomal-related genes as part of the Coordinated 
Lysosomal Expression and Regulation (CLEAR) network [178-180]. Treatments that induce 
autophagy, including nutrient deprivation and inhibition of mTOR, also promote TFEB activity 
[178, 179, 181-183]. Another recently characterized mechanism of inducing autophagy is 
exercise. Treadmill running for 30 minutes is sufficient to significantly stimulate autophagy in a 
Bcl-2-dependent manner in vivo [184]. In spite of evidence suggesting that changes in protein 
quality control occur in SBMA, the degree to which regulatory effectors or responses to 
physiologic stimuli of autophagy are involved or differentially affected in SBMA is unknown 
[153, 170, 185, 186]. 
 
1.2.3 Autophagy and SBMA 
 Although the nuclear localized polyQ AR is not an autophagic substrate, autophagy is 
able to degrade the mutant protein upon its sequestration within the cytoplasm [98]. Furthermore, 
expression of the mutant AR itself is sufficient to induce autophagy in SBMA cell and animal 
models, although the mechanism underlying this observation has not been explored [170, 185]. 
Consistent with these findings, as briefly discussed above we have demonstrated that genetic 
manipulations that modulate autophagy have a significant influence on the phenotype of SBMA. 
We implicated autophagy using a knock-in mouse model we previously generated in which gene 
targeting was used to exchange much of mouse Ar exon 1 with human sequence while inserting 
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glutamine tracts encoded by 21 or 113 CAG repeats [107, 187]. While AR21Q males are similar 
to wild type littermates, AR113Q males exhibit hormone-dependent weight loss, deficits in 
muscle strength and early death [101, 107]. In AR113Q knock-in mice null for the unfolded 
protein response effector CHOP, autophagy is upregulated and mice demonstrate an exacerbation 
of disease [152]. Conversely, genetic inhibition of autophagy through haplosufficient expression 
of Beclin-1 reduces autophagic levels in AR113Q mice, mitigates skeletal muscle atrophy and 
prolongs survival [152]. These data indicate that excessive activation of autophagy is detrimental 
to SBMA mice. 
 
1.3 Small ubiquitin-like modifier (SUMO)  
 
1.3.1 Essential features of SUMO modification  
As discussed in section 1.1.2, modulation of AR function and alteration of steps critical 
to SBMA pathogenesis is accomplished through regulatory mechanisms that include post-
translational modifications. One such modification is SUMO, a 10-kDa protein that selectively 
modifies substrates at conserved lysine residues and mediates diverse alteration of protein 
activity and stability [188]. The SUMO family includes four distinct mammalian paralogues, 
SUMO1 to SUMO4 [189, 190]. SUMO1 is essential for embryonic viability and normal 
development, and serves functions distinct from the other SUMO paralogues [191-194]. SUMO2 
and SUMO3 share 97% sequence similarity but only 50% with SUMO1, and these two 
paralogues are often grouped together as SUMO2/3 [195]. All three paralogues are ubiqitously 
expressed and well-characterized, whereas corresponding molecular and functional aspects of 
SUMO4 remain to be defined [189]. 
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Although SUMO shares only about 20% sequence homology with ubiquitin, the 
pathways involved in mediating covalent attachment of each modification are similar. 
Maturation of a pro-SUMO protein involves proteolytic pre-processing followed by interactions 
with E1 activating, E2 conjugating, and E3 ligating enzymes [196-200]. Single entities constitute 
the SUMO E1 (SAE1/SAE2 complex, where SAE = SUMO-activating enzyme) and SUMO E2 
(Ubc9), but the identity and involvement of SUMO E3 ligases varies in a substrate-specific 
manner and, unlike in the case of ubiquitin, are dispensible for SUMO ligation [201-204]. 
Similar to ubiquitin modification, multiple monomers of SUMO2/3 can be conjugated together 
to form polymeric chains, which confer additional levels of complexity to SUMO function, 
interactions, and signaling [205]. Moreover, SUMOylation is characterized by a high degree of 
reversibility. The SUMO system includes isopeptidases with specific activities directed against 
deconjugating the SUMO moiety and editing polySUMO chains in response to cellular and 
environmental cues, thereby allowing for further dynamic modulation of protein function [206]. 
 
1.3.2 SUMOylation and neurodegeneration 
 Apart from regulating diverse cellular processes of the nervous system under 
physiological circumstances, SUMO has been implicated in modifying critical aspects of 
neurologic disease. SUMO has been detected in the intranuclear inclusions characteristic of 
neurodegenerative diseases, and several of the mutant proteins constituent to these aggregates are 
endogenous SUMO substrates [207, 208]. The ability of SUMO to modulate substrate solubility 
and aggregation or compete for ubiquitination can either disrupt or enhance pathogenesis 
depending on the disease context [207]. For instance, enhanced SUMOylation of mutant 
atrophin-1, huntingtin, and SOD1 results in increased stability of the mutant proteins [209-212]. 
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Subsequently, SUMOylation increases aggregation of atrophin-1 and SOD1 but decreases 
aggregation of huntingtin, with the common result for all three mutant proteins culminating in 
enhanced cytotoxicity. For huntingtin, this SUMO-dependent effect is catalyzed by the striatally 
enriched G-protein, Rhes [211]. Similarly, enhanced monoSUMOylation through expression of 
the K11R variant of SUMO3, which prevents polySUMO3 chain formation, potentiates A 
generation, whereas polySUMO chains with wild type SUMO3 attenuate amyloidogenesis [213]. 
Detrimental or modulatory effects of SUMOylation in other cases of neurodegeneration are 
documented with ataxin-1, DJ-1 L166P mutant, and tau [214-216]. Further research will be 
necessary to define optimal therapeutic targets in the SUMO pathway to modify aspects of 
proteotoxicity in neurodegeneration. 
 
1.3.3 SUMO modification of AR and SBMA 
In addition to the proteins detailed in the previous section, the AR is an established 
SUMO substrate with two conserved synergy control (SC) motifs in the NTD that serve as sites 
of SUMO modification [63, 217]. The SC motif sequence consists of P/G-x(0-4)-I/V-x-K-D/E-
x(0-4)-P/G (where P = proline, G = glycine, x = any amino acid, I = isoleucine, V = valine, K = 
lysine, D = aspartate, E = glutamate), and SUMOylation at the constituent lysine residue results 
in inhibition of transactivational activity [63, 217, 218]. This aspect of AR transcriptional control 
by SUMO informs investigative targeting of the SUMO pathway for SBMA, since a primary 
feature of the disease is AR loss of function and androgen insensitivity. This loss of function 
phenotype may be rescued by potentiating polyQ AR transactivation by disrupting SUMOylation 
(further detailed in sections 1.1.1 and 1.1.4).  
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The other major feature of SBMA is the degenerative phenotype mediated by 
proteotoxicity from the polyQ AR, and this toxic gain of function is both distinct from the partial 
loss of function of the polyQ AR and is modified by SUMO.  In Drosophila, expression of 
truncated polyQ AR results in aggregation and neurotoxicity, and a loss of function mutant of the 
SUMO E1 component Uba2 worsens this degenerative phenotype, suggesting that diminished 
AR SUMOylation exacerbates pathogenesis [138] . In cell culture models of SBMA, increased 
expression of SUMO3 enhances SUMOylation of polyQ AR and reduces its aggregation, and 
this effect can be abrogated by mutating the SUMO acceptor lysines, suggesting that direct 
SUMOylation of the AR modifies toxicity by preventing or disrupting oligmerization  [69]. 
However, the degree to which SUMO affects SBMA in vivo and the mechanisms by which it 
modifies pathogenesis remain to be determined. 
 
1.4 Research Objectives 
Despite extensive advances in understanding the mechanisms of pathogenesis in SBMA, 
many key features pertaining to molecular determinants of disease development are not yet 
established or remain controversial. The work presented in this dissertation approaches these 
unresolved questions by investigating two cellular processes associated with modifying 
neurodegenerative disease, autophagy and SUMOylation. The first objective is to define the 
manner and extent to which autophagy is altered in SBMA. In chapter 2, I characterize the 
upregulation of autophagy in cell and animal models of SBMA, identify the transcription factors 
TFEB/ZKSCAN3 underlying these pathologic changes, and establish the increased responsivity 
to physiologic stimulation of autophagy in SBMA mice. The second objective is to examine the 
degree to which SUMO modification affects aspects of the SBMA phenotype. In chapter 3, I 
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show that genetically disrupting SUMOylation of polyQ AR dramatically enhances receptor 
transactivation, and mice expressing non-SUMOylatable polyQ AR have improved exercise 
endurance and are rescued from early death. In conclusion, these results indentify discrete targets 
in cellular pathways definitively implicated in SBMA pathogenesis, and strategies aimed at 
inhibiting or disrupting these processes may be of therapeutic benefit in human patients. 
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Chapter 21 
 
Transcriptional dysregulation of TFEB/ZKSCAN3 targets underlies enhanced 
autophagy in spinobulbar muscular atrophy 
 
2.1  Abstract 
 Spinobulbar muscular atrophy (SBMA) is an inherited neuromuscular disorder caused by 
the expansion of a CAG repeat encoding a polyglutamine (polyQ) tract in exon 1 of the androgen 
receptor (AR) gene. SBMA demonstrates androgen-dependent toxicity due to unfolding and 
aggregation of the mutant protein. There are currently no disease-modifying therapies, but of 
increasing interest for therapeutic targeting is autophagy, a highly conserved cellular process 
mediating protein quality control. We have previously shown that genetic manipulations 
inhibiting autophagy diminish skeletal muscle atrophy and extend lifespan of AR113Q knock-in 
mice while those inducing autophagy worsen muscle atrophy, suggesting that chronic, aberrant 
upregulation of autophagy contributes to pathogenesis. Since the degree to which autophagy is 
altered in SBMA and the mechanisms responsible for such alterations are incompletely defined, 
we sought to delineate autophagic status in SBMA using both cellular and mouse models. Here, 
we confirm that autophagy is induced in cellular and knock-in mouse models of SBMA and 
show that the transcription factors TFEB and ZKSCAN3 operate in opposing roles to underlie 
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 This chapter is in preparation for submission for publication. 
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these changes. We demonstrate upregulation of TFEB target genes in skeletal muscle from 
AR113Q male mice and SBMA patients. Furthermore, we observe a greater response in 
AR113Q mice to physiological stimulation of autophagy by both nutrient starvation and 
exercise. Together, our results indicate that transcriptional signaling contributes to autophagic 
dysregulation and provide a mechanistic framework for the pathologic increase of autophagic 
responsiveness in SBMA. 
 
2.2 Introduction 
Spinobulbar muscular atrophy (SBMA) is one of nine untreatable diseases caused by 
CAG/glutamine tract expansions [13]. SBMA is an X-linked, progressive neurodegenerative 
disorder of adult-onset primarily affecting lower motor neurons and skeletal muscle. The 
polyglutamine (polyQ) expansion critical for SBMA pathogenesis occurs in exon 1 of the 
androgen receptor (AR) gene. The polyQ AR protein acquires a toxic gain of function by 
undergoing aberrant unfolding, oligomerization and metabolism dependent on binding the 
cognate ligands testosterone and dihydrotestosterone (DHT) [91, 92]. These steps are critical for 
mediating toxicity in target tissues, and the dependence of disease development on androgen 
underlies the exclusive incidence of SBMA in men [21]. Additionally, the polyQ AR exhibits a 
partial loss of transactivation function [36, 47], correlating with features of androgen 
insensitivity including gynecomastia and reduced fertility in SBMA patients. Despite progress 
over the past two decades in characterizing key aspects of neuromuscular toxicity and endocrine 
disruption in SBMA, mechanisms that are essential to pathogenesis remain poorly understood 
and available therapies are of limited utility. 
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One essential, highly conserved mechanism of protein quality control involved in 
modifying neurodegenerative disease is macroautophagy, or simply autophagy [171, 219, 220]. 
The autophagic process consists of the envelopment of cytoplasmic organelles, proteins, and 
other macromolecules within a double-membraned phagophore that ultimately resolves into a 
mature autophagosome, and this vesicular body is transported to and fuses with the lysosome to 
form an autolysosome and degrade the sequestered cargo [171-174]. Multiple regulatory 
mechanisms of autophagy have been thoroughly studied and classified, and considerable 
attention has focused on transcriptional modulation through factors including TFEB and 
ZKSCAN3. TFEB is a basic helix-loop-helix, leucine-zipper member of the MITF/TFE family 
that not only coordinates expression of genes controlling lysosomal biogenesis but also, in a 
recently characterized role, regulates autophagy [178-180]. ZKSCAN3 is a zinc finger protein 
with Krüppel-associated box (KRAB) and SRE-ZBP/CTfin-51/AQ-1/Number 18 cDNA-
homology (SCAN) domains that has recently been implicated in regulating TFEB target genes as 
a master repressor of autophagy [221]. TFEB is prompted to activate autophagy-related gene 
expression through established induction mechanisms of autophagy, including nutrient 
withdrawal and treatment with rapamycin [178, 179, 181-183]. In contrast, ZKSCAN3 activity is 
inhibited by these manipulations and operates in a manner antagonistic to TFEB [221]. 
At the organismal level, physiologic stimulation of autophagy is conventionally achieved 
through starvation and mTOR inhibition, but recent studies have also described alternative 
mechanisms. In particular, running exercise is capable of acutely inducing autophagy, and mice 
expressing the autophagy marker microtubule-associated light chain 3 (LC3) tagged with GFP 
demonstrate accumulation of fluorescent autophagic structures within 30 minutes that peak 
within 80 minutes while running on a treadmill [184]. This induction of autophagy occurs under 
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strict control by Beclin-1/BCL-2 associated machinery, which coordinate stimulus-induced 
autophagy in vivo as evidenced by the observation that BCL-2 mutant mice are unable to activate 
Beclin-1 and induce exercise-stimulated autophagy. These studies of exercise-induced autophagy 
are notable for revealing inductive influence in both skeletal muscle and spinal cord, two 
principal sites of pathology in SBMA [184, 222]. 
 The extent to which pathways of proteostasis interact with or are altered by pathogenic 
mechanisms in neurodegenerative diseases, including SBMA, is not fully understood. Adverse 
effects on protein quality control in SBMA have been described for the unfolded protein 
response, the ubiquitin-proteasome system, and autophagy [153, 170, 185, 186]. Moreover, 
expression of polyQ AR correlates with autophagic activity, and antagonizing autophagy in vivo 
ameliorates the SBMA phenotype [152, 170, 185]. Based on these findings, we hypothesized that 
autophagy is aberrantly activated in SBMA, which underlies the previously documented 
deleterious influence of autophagy to disease pathogenesis. We test this notion by analyzing 
aspects of autophagic induction, flux, and regulation in both cellular and animal models of 
SBMA. We confirm that autophagy is induced in the context of the polyQ AR both in vitro and 
in vivo, implicate TFEB in the increased expression of autophagy-related genes in SBMA mice 
and human patients, and establish that autophagic induction by nutrient deprivation and exercise 
is more highly activated in SBMA mice compared to healthy controls. These results define the 
mechanism underlying aberrant upregulation of autophagy in SBMA and provide discrete targets 
in the autophagic pathway for further investigation and therapeutic design. 
 
2.3 Results 
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2.3.1 Expanded glutamine AR promotes autophagy 
To investigate autophagy in SBMA, we initially studied PC12 cells that stably express 
tetracycline-inducible full-length human AR with 10 or 112 glutamines [97]. We observed 
higher basal levels of the autophagosome marker LC3-II in cells expressing AR112Q (Fig. 
2.1A). Serum starvation promoted robust conversion of LC3-I to LC3-II in both cell lines, but 
this process was significantly more pronounced in AR112Q cells (Fig. 2.1A). To determine 
whether these elevated LC3-II levels resulted from enhanced activation of autophagy or impaired 
flux, we examined levels of the autophagic substrate p62 and assessed levels of LC3-II with and 
without lysosomal inhibition. Both of these are standard assays for evaluating autophagic flux 
[223]. AR112Q cells demonstrated significant clearance of p62 in response to serum starvation 
(Fig. 2.1A).  Furthermore, treatment with the lysosomal protease inhibitors E64d and pepstatin A 
led to similarly enhanced accumulation of LC3-II in both AR10Q and AR112Q cells (Fig. 2.1B). 
These results suggest that autophagic markers accumulate to a greater extent with AR112Q 
expression primarily due to aberrant upregulation of autophagy rather than compromised 
autophagic flux. 
We then sought to define which signaling mechanisms are responsible for the increased 
activation of autophagy in SBMA. To do this, we first probed the mTOR pathway, since mTOR 
is a serine/threonine kinase that serves as a principal regulator of autophagy [224-226]. We 
found that phosphorylation of mTOR and p70 S6 kinase, a downstream effector of the mTOR 
pathway, was decreased in both cell lines, but this reduction was significantly greater in AR112Q 
cells (Fig. 2.1C). Lower mTOR activity and phosphorylation are consistent with disinhibition of  
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Figure 2.1 Expanded polyglutamine AR promotes autophagy. (A) AR10Q and 
AR112Q cells were serum starved to induce autophagy. Lysates were analyzed for LC3 and p62 
(n=3). Data are mean +/- SEM. *p<0.05, ***p<0.001. (B) Autophagic flux in AR10Q and 
AR112Q cells (n=3) determined by quantifying normalized LC3-II band intensities and 
subtracting the difference of fed E64d/pepstatin A-treated and untreated cells from the difference 
of starved E64d/pepstatin A-treated and untreated cells. Data are mean +/- SEM. n.s., not 
significant. (C) AR10Q and AR112Q cells were starved, and phospho-status of the mTOR 
pathway was analyzed. Data are mean +/- SEM. *p<0.05, ***p<0.001, ****p<0.0001. 
 
autophagy, since mTOR negatively regulates autophagic induction [224-226]. In contrast, 
phosphorylation of extracellular regulated kinases ERK1/2, which comprise another set of 
autophagy regulators that can function independently of mTOR [227-231], was unchanged 
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regardless of serum supplementation (Fig. 2.1C). These results indicate that autophagy is 
selectively upregulated with expression of AR112Q in these cells due to inhibition of the mTOR 
pathway. 
 
2.3.2 Transcription factors that regulate autophagy partition in a glutamine 
length-dependent manner 
Recent studies have shown that transcription factor EB controls expression of autophagy-
related genes, and its activity and nuclear localization are negatively regulated by mTOR [181-
183]. Additionally, the zinc-finger protein ZKSCAN3 has been characterized as a transcriptional 
antagonist to autophagy, functioning oppositely and in concert with TFEB [221]. Given our 
observations of increased autophagy and depressed mTOR activity in the context of AR112Q, 
we postulated that TFEB and ZKSCAN3 act as major determinants of autophagic upregulation in 
SBMA. To test this hypothesis, we prepared nuclear lysates of PC12 cells subjected to serum 
starvation and determined the relative localization of each transcription factor. Consistent with 
our findings of increased autophagic induction and reduced mTOR activity in AR112Q cells, we 
found that the transcriptional activator TFEB displayed significantly greater nuclear localization 
upon serum starvation while the repressor ZKSCAN3 exhibited diminished nuclear localization 
even under fed conditions (Fig. 2.2A). Similarly, immunofluorescence demonstrated nuclear 
localization of TFEB in AR10Q cells with concomitant cytoplasmic translocation of ZKSCAN3 
only after starvation. In contrast, nuclear TFEB and cytoplasmic ZKSCAN3 were detected in 
AR112Q cells even when serum supplemented (Fig. 2.2B). Together, our results suggest that 
autophagy is primed for activation with depressed mTOR activity in the presence of AR112Q,  
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Figure 2.2 Transcription factors that regulate autophagy display glutamine length-
dependent changes in intracellular localization. (A) Nuclear lysates prepared from 
serum starved and fed AR10Q and AR112Q cells were analyzed for TFEB and ZKSCAN3. Data 
are mean +/- SEM (n=3). *p<0.05, **p<0.01. (B) AR10Q and AR112Q cells were serum starved 
or fed and immunostained for TFEB and ZKSCAN3. 
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2.3.3 Polyglutamine AR increases autophagy in vivo. 
To corroborate the autophagic changes we observed in PC12 cells, we probed markers of 
autophagy in AR21Q and AR113Q knock-in male mice. Consistent with our previous 
observations, we found significantly higher LC3-I to LC3-II conversion in skeletal muscle and 
spinal cord in AR113Q males, and observed that this difference became more pronounced in 
muscle when autophagy was induced by starvation (Fig. 2.3A). Additionally, total ubiquitinated 
proteins and p62 from the insoluble fraction were also increased in AR113Q muscle (Fig. 2.3A). 
Autophagic puncta, which we detected by co-expressing a GFP-LC3 transgene [232], 
accumulated in skeletal muscle after starvation of both AR21Q and AR113Q males. This 
accumulation of autophagic puncta occurred to a greater extent in starved AR113Q mice, in line 
with our biochemical data showing enhanced autophagy in PC12 cells expressing the polyQ AR 
(Fig. 2.1B). To confirm equivalent levels of autophagic flux in both knock-in lines, we inhibited 
autophagosome to lysosome fusion in vivo by administering colchicine [233]. Starved, 
colchicine-treated mice of both genotypes showed similarly enhanced accumulation of LC3-II 
(Fig. 2.3C). We conclude that autophagic induction is increased in AR113Q knock-in males 
without accompanying loss of autophagic flux.  
 
2.3.4 AR113Q promotes TFEB activity in vivo. 
To test whether TFEB activity is increased in AR113Q mice, we prepared nuclear lysates 
of skeletal muscle from each knock-in line and assessed TFEB localization. We found that, as 
occurs in tetracycline-regulated PC12 cells, the mouse orthologue TCFEB displays greater 
nuclear localization in AR113Q compared to AR21Q male mice (Fig. 2.4A). To determine  
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Figure 2.3 Expression of the polyglutamine AR increases autophagy in vivo. (A) 
Quadriceps and spinal cord from fed or starved AR21Q and AR113Q micewere analyzed for 
markers of autophagy. Data are mean +/- SEM (n=3). *p<0.05, **p<0.01. (B) Autophagic puncta 
in quadriceps from AR21Q and AR113Q mice expressing GFP-LC3 were analyzed by 
immunostain. Data are mean +/- SEM (n=3). *p<0.05. (C) Autophagic flux was determined after 
treatment with colchicine and analysis of accumulated LC3-II. Data are mean +/- SEM (n=3). 
n.s., not significant. 
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whether enhanced nuclear localization correlated with upregulation of autophagy-related genes, 
we assayed the expression profile of a select set of previously identified TFEB target genes [178-
180]. Quantitative RT-PCR confirmed that autophagy-related genes containing TFEB binding 
sites in their promoter regions demonstrated increased expression levels in AR113Q mice, and 
that this difference was more pronounced for many genes after starvation (Fig. 2.4B). Similarly, 
we found that several TFEB target genes were also expressed at higher levels in skeletal muscle 
biopsies from SBMA patients than controls (Fig. 2.4C). These glutamine length- and starvation-
dependent transcriptional changes in AR113Q mice were not observed in target genes of 
FOXO3a (Fig 4D), another important regulator of autophagy in skeletal muscle [234, 235]. 
Taken together, these data indicate that SBMA results in increased activity specific to TFEB and, 
consequently, enhanced expression of autophagy-related genes. 
 
2.3.5 Expanded polyglutamine AR enhances autophagic response to exercise.
 Finally, we sought to explore whether enhanced TFEB activity and increased expression 
of autophagy-related genes lead to an augmented autophagic response following an acute, 
physiologically relevant stimulus. Recently, He et al. established exercise as a potent inducer of 
autophagy in vivo [184]. To corroborate the effect of exercise in AR knock-in mice, we ran 
AR21Q/GFP-LC3 and AR113Q/GFP-LC3 male mice on a treadmill and evaluated the formation 
of GFP-positive autophagic puncta in quadriceps muscle. After 80 minutes of exercise, both 
knock-in lines demonstrated accumulation of autophagic puncta akin to induction by starvation 
(Fig. 2.5A). We then asked if each AR line responded equivalently to autophagic induction by 
exercise. To accomplish this we followed markers of autophagy biochemically and found that 
exercise stimulated GFP-LC3-II accumulation to a higher degree in AR21Q muscle (Fig. 2.5B).  
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Figure 2.4 Expanded polyglutamine AR promotes TFEB activity in vivo. (A) Nuclear 
lysates from quadriceps muscle were prepared from AR21Q and AR113Q mice and analyzed for 
TCFEB, the murine orthologue of TFEB. Data are mean +/- SEM (n=3). **p<0.01. (B) Total 
RNA was extracted from quadriceps of fed and starved AR21Q and AR113Q mice (n=6 per 
group), and transcripts of genes regulated by TCFEB were analyzed by qPCR. Data mean +/- 
SEM. *p<0.05, **p<0.01. (C) Transcripts of TFEB-regulated genes were analyzed by qPCR in 
muscle samples from SBMA and control patients (n=3 per group). Data are mean +/- SEM. 
**p<0.01. Color coding same as (B). (D) Transcripts of FOXO3a target genes were analyzed by 
qPCR in the quadriceps described in (B). Data are mean +/- SEM. n.s., not significant. 
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We hypothesized that this difference reflected enhanced clearance of autophagic substrates in 
AR113Q males after acute stimulation of autophagy. We tested this notion by evaluating levels 
of p62 and free GFP as indicators of autophagic flux. Free GFP is produced after GFP-LC3-II is 
delivered to lysosomes and the LC3-II portion of the fusion protein is degraded [236-238]. 
Western analysis of these autophagic markers after exercise revealed similar degradation of 
endogenous p62 in both knock-in lines, but a striking absence of free GFP in AR113Q mice; in 
contrast, free GFP robustly accumulated in skeletal muscle of exercised AR21Q mice (Fig. 
2.5B). Our analysis suggests rapid clearance of the GFP-LC3 fusion protein in AR113Q males. 
We conclude that exercise promotes autophagy in both knock-in lines. The enhanced clearance 
of GFP-LC3 supports greater autophagic flux in skeletal muscle of AR113Q males, indicative of 
enhanced responsiveness to physiologic stimuli in these mice.  
Figure 2.5 Expanded polyglutamine AR 
enhances autophagic response to exercise. 
(A) Autophagic puncta in quadriceps from rested or 
exercised AR21Q and AR113Q mice expressing 
GFP-LC3 analyzed by immunostain. (B) Mice were 
exercised for 80 minutes, and lysates of quadriceps 
muscle were collected and analyzed for GFP-LC3, 
free GFP and p62. Data mean +/- SEM (n=3). 
*p<0.05, **p<0.01. 
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2.4 Discussion 
Previous studies suggested an exacerbatory role for autophagy in SBMA, since genetic 
ablations that either induce or suppress autophagy worsen or ameliorate the SBMA phenotype, 
respectively [152]. Consistent with those findings, we show that autophagy is upregulated in 
models of SBMA. Both AR112Q cells and AR113Q mice exhibit increased levels of LC3-II, 
suggestive of higher production of autophagosomes (Fig. 2.1A and 2.3A). These changes were 
accentuated by stimulation of autophagy by nutrient deprivation. The accumulation of autophagy 
markers was not due to impaired autophagic flux, since pharmacologic inhibition of lysosomal-
mediated degradation indicated completion of flux both in vitro and in vivo (Fig. 2.1B and 
2.3C). In addition, these biochemical data are associated with increased nuclear translocation of 
TFEB in both polyQ AR cells and AR113Q mice (Fig. 2.2 and 2.4). The relative shifts in 
localization for TFEB and ZKSCAN3 favoring TFEB activity resulted in predicted enhancement 
of TFEB target genes that regulate autophagy, both in SBMA mice and human patients (Fig. 
2.4). Our results define broad changes in the autophagic system that corroborate the postulated 
activation of autophagy in SBMA. Consequently, proposed therapeutic strategies aimed at 
increasing autophagy in other neurodegenerative disorders may prove inappropriate, if not more 
deleterious, to pathogenesis of SBMA [220, 239, 240]. 
  Supporting the notion that enhanced autophagy contributes to the pathogenesis of SBMA, 
we previously demonstrated that levels of autophagy directly correlate with skeletal muscle 
atrophy in AR113Q knock-in mice [152]. Despite evidence of motor neuron loss and denervation 
in SBMA muscle [1, 241], the elevated expression of TFEB targets documented in this study is 
muscle autonomous and dependent on polyQ AR expression. This conclusion is based in part on 
our observation that surgical denervation in WT AR mice is unable to recapitulate or sustain the 
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transcriptional phenotype (data not shown). In addition to the AR113Q-dependent nature of 
increased autophagy under resting conditions, stimulation of autophagy is augmented in response 
to nutrient deprivation and exercise, leading to marked degradation of protein substrates through 
the autophagic pathway. These results characterize a striking instance of neurodegenerative 
disease in which regulated control of autophagy is compromised, and it is likely that these 
changes effect deleterious contributions to pathogenesis, since critical components of skeletal 
muscle are autophagic substrates [242]. 
 Mechanisms of proteostasis are essential mediators of muscle integrity, and balancing the 
degradative and protective roles of protein quality control in muscle is critical for muscle 
maintenance and appropriately responding to nutrient deprivation, mechanical stress, and disuse 
atrophy. The ubiquitin-proteasome system (UPS) serves a pivotal role in muscle protein 
catabolism, and enhanced or aberrant UPS activity is responsible for physiologic and pathologic 
forms of atrophy [243]. However, it is unlikely that the UPS acts as the primary mediator of 
muscle wasting in SBMA, since the muscle-specific ubiquitin E3 ligases atrogin-1/MAFbx and 
Murf1 that mediate muscle atrophy are not upregulated in AR113Q and AR97Q mice [152, 158, 
244, 245]. In contrast, several groups have demonstrated that dysregulated autophagy is 
sufficient to promote atrophy in muscle. Loss of Runx1 models disuse and deneveration changes 
in skeletal muscle and causes atrophy through disinhibited autophagy [246]. Similarly, 
denervation- and fasting-induced atrophy has been shown to occur through FOXO3-mediated 
induction of autophagy [234, 235]. Furthermore, increased autophagy is instrumental in 
mediating or enhancing myopathy in neuromuscular disorders [247-249]. Our findings here are 
consistent with genetic and pharmacologic manipulations of IGF-1 that mitigate SBMA in a 
muscle-specific manner, since these ameliorative effects are dependent on enhanced activation of 
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the autophagic repressor Akt [52, 158, 250].   It will be important for future studies to weigh the 
therapeutic potential of inducing autophagy to address proteinopathies against our observation of 
detrimentally elevated autophagy in SBMA. 
We also observed correlative reductions in phosphorylation events within the mTOR 
pathway (Fig. 2.1C). Although mTOR is an established master regulator of autophagy and has 
been shown to interact with TFEB, and despite our data in AR112Q cells consistent with these 
aspects of mTOR function, conflicting evidence remains regarding the precise regulative 
mechanism of TFEB inhibition through phosphorylation by mTOR or ERK2 [178, 181-183]. Our 
data in vitro are compatible with mTOR-mediated modulation of TFEB due to unaltered ERK1/2 
signaling regardless of glutamine tract length or nutrient provision (Fig. 2.1C), and it will be 
necessary in future studies to analyze these regulatory determinants in vivo to further expand our 
understanding of the TFEB pathway. Moreover, although elucidating the involvement of TFEB 
and its regulatory pathways will be valuable for therapeutic targeting, the causal determinants 
directly linking the mutant AR to changes in mTOR and TFEB remain to be defined. Overall, we 
have delineated specific alterations in the autophagic pathway occurring in SBMA and particular 
effectors associated with these changes. It is likely that these alterations constitute a 
compensatory mechanism in response to pathogenic insults introduced by the polyQ AR, and 
determination of these molecular triggers is expected to yield valuable information for 
counteracting these insults and, in turn, treating SBMA. 
 
2.5 Materials and Methods 
 
2.5.1 Materials 
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 Lysosomal protease inhibitors E64d and pepstatin A, normal saline tablets, and 
colchicine were from Sigma. For preparation of nuclear lysates from mouse tissue, the following 
buffers were used: NB1 (10mM Tris pH 8.0, 10mM NaCl, 3mM MgCl2, 0.5mM DTT, 0.1% 
Triton X-100, 0.1M sucrose), NB2 (10mM Tris pH 8.0, 10mM NaCl, 3mM MgCl2, 0.5mM DTT, 
0.1% Triton X-100, 0.25M sucrose), NB3 (10mM Tris pH 8.0, 5mM MgCl2, 0.5mM DTT, 
0.33M sucrose), EB (25mM HEPES pH 7.8, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 
0.5mM DTT, 25% glycerol), and Z (25mM HEPES pH 7.8, 12.5mM MgCl2, 1mM DTT, 0.1M 
KCl, 0.1% NP40, 20% glycerol). Antibodies against indicated proteins and their respective 
vendors were as follows: AR (N-20) was from Santa Cruz; GAPDH (6C5) was from Abcam; 
GFP (A11122) was from Invitrogen; LC3 (NB600-1384) and p62 (2C11) were from Novus 
Biologicals; Lamin A (MAB3540), phospho-mTOR (09-213), phospho-ERK1/2 (12D4), total 
ERK1/2 (06-182), and total p70 S6K (07-402) were from Millipore; phospho-p70 S6K (9204) 
and total mTOR (2972) were from Cell Signaling; Tfeb (MBS120432) was from MyBioSource; 
ZKSCAN3 (AV33609) was from Sigma. HRP-tagged secondary antibodies were from Bio-Rad. 
Alexa Fluor 488- and 594-conjugated secondary antibodies were from Invitrogen. 
 
2.5.2 Cell culture 
 PC12 cells stably transfected with tetracycline-inducible forms of AR were described 
previously [97]. AR expression was induced with 500 ng/mL doxycycline (Clontech) in the 
presence of 10nM R1881. Cells were maintained in phenol red-free Dulbecco’s modified Eagle’s 
medium (Invitrogen) supplemented with 15% charcoal-stripped horse serum (Invitrogen), 10% 
charcoal-stripped fetal bovine serum (Thermo Scientific), 100 units/mL penicillin/streptomycin 
(Invitrogen), 200µg/mL hygromycin B (Invitrogen), and 100 µg/mL G418 (Invitrogen) in 15% 
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CO2 at 37ºC. Serum starvation was performed in Hank’s Balanced Salt Solution (HBSS, 
Invitrogen) supplemented with doxycycline and R1881 for 4 hours. To analyze autophagic flux, 
PC12 cells were induced to express AR for 44 hours then fed or starved in HBSS with 
E64d/pepstatin A (10µg/mL each) or DMSO vehicle for 4 hours.  Autophagic flux was then 
determined by subtracting the difference of LC3-II levels in serum starved cells with and without 
E64d/Pepstatin A treatment from the difference of LC3-II levels in serum supplemented cells 
with and without E64d/Pepstatin A. 
 
2.5.3 Mouse studies 
 Generation of knock-in mice with targeted AR allele containing 21 or 113 CAG repeats 
has been previously described [107, 187]. GFP-LC3 transgenic mice were kindly provided by 
Jun-Lin Guan (University of Michigan) and have been described previously [232]. Mice were 
group housed in an SPF facility and provided with food and water ad libitum. Genotypes were 
confirmed by PCR of tail biopsy-derived DNA. AR knock-in mice were genotyped with forward 
primer 5’-CCAGAATCTGTTCCAGAGCGTG-3’ and reverse primers 5’-
TGTTCCCCTGGACTCAGATG-3’ and 5’-GCACTCCAGGGCCGACTGCG-3’ in a 2:2:1 
ratio, respectively. GFP-LC3 mice were genotyped with forward primer 5’-
TCCTGCTGGAGTTCGTGACCG-3’ and reverse primer 5’-
TTGCGAATTCTCAGCCGTCTTCATCTCTCTCGC-3’ to detect the GFP-LC3 transgene and 
in a separate reaction with forward primer 5’-TGAGCGAGCTCATCAAGATAATCAGGT-3’ 
and reverse primer 5’-GTTAGCATTGAGCTGCAAGCGCCGTCT-3’ to detect the endogenous 
LC3 allele.  
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 Skeletal muscle and spinal cord were collected from adult male knock-in mice 13 to 15 
weeks old and flash frozen for biochemical analysis or mounted in OCT for cryosectioning. For 
morphologic analysis of autophagy in skeletal muscle, AR knock-in mice were crossed with 
GFP-LC3 mice to generate bigenic 21Q/GFP-LC3 and 113Q/GFP-LC3 mice. To induce 
autophagy, mice were starved for 48 hours and provided with water ad libitum. To analyze 
autophagic flux, mice were starved for 48 hours and treated with intraperitoneal injections of 
normal saline or colchicine (0.4mg/kg/day). Autophagic flux was then determined by subtracting 
the level of LC3-II in saline treated mice from the level of LC3-II in colchicine treated mice.  
 For exercise studies, a treadmill protocol was implemented as previously described [184]. 
Mice were trained on an Exer3/6 treadmill (Columbus Instruments) for two days. On day 1, mice 
were run at 8 meters/minute for 5 minutes, and on day 2 mice were run at 8 meters/minute for 5 
minutes then 10 meters/minute for 5 minutes. After training, mice were run on day 3 for 40 
minutes at 10 meters/min, then for 30 minutes with increasing speed 1 meter/minute every 10 
minutes, and finally for 20 minutes with increasing speed 1 meter/minute every 5 minutes for a 
total of 80 minutes of exercise. Mice were then immediately sacrificed and perfused with 4% 
paraformaldehyde and proximal hind limb muscles were collected. The University of Michigan 
Committee on Use and Care of Animals approved all procedures involving mice in compliance 
with the NIH Guidelines for the Care and Use of Experimental Animals.  
 
2.5.4 Gene expression analysis 
 Total RNA was extracted from proximal hind limb muscle from AR knock-in mice after 
the indicated treatments in triplicate with Trizol (Sigma). Reverse transcription was performed 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to 
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manufacturer’s protocol. Total RNA was similarly prepared from anonymized skeletal muscle 
biopsies from SBMA patients and controls as previously described [152]. Quantitative PCR was 
performed with FastStart TaqMan Probe Master/Rox Master Mix (Roche) on a 7500 Real-Time 
PCR SDS System with supplied software (Applied Biosystems) using gene-specific primers with 
FAM-labeled probes purchased from Applied Biosystems (Human: LAMP1, Hs00174766_m1; 
MAP1LC3, Hs01076567_g1; VPS11, Hs00222240_m1; VPS18, Hs00363585_m1. Mouse: 
Bnip3, Mm01275601_g1; Fbxo32, Mm00499518_m1; Lamp1, Mm00495262_m1; Map1lc3, 
Mm00782868_sH; Murf1, Mm00185221_m1; Sqstm1, Mm00448091_m1; Tcfeb, 
Mm00448968_m1; Vps11, Mm01168594_m1; Vps18, Mm00552119_m1). Relative expression 
levels were calculated by comparing with the expression of 18S rRNA. 
 
2.5.5 Analysis of protein expression 
 Cells were washed and collected in PBS, then harvested and lysed in RIPA buffer 
supplemented with phosphatase and protease inhibitors. Lysates were clarified at 15,000 x g for 
15 minutes at 4ºC. Nuclear and cytoplasmic lysates were prepared with NE-PER Extraction Kit 
(Thermo Scientific) according to manufacturer’s instructions. For tissue analyses, proximal hind 
limb muscle and lumbar spinal cord from AR knock-in mice were minced, lysed, and 
homogenized in RIPA buffer containing phosphatase and protease inhibitors. Lysates were 
clarified at 13,000 x g for 10 minutes at 4ºC. 
 Nuclear lysates from proximal hindlimb muscle were prepared as follows. Frozen tissue 
was pulverized, lysed in NB1 buffer, homogenized with a type A dounce homogenizer, mixed 
with NB2 buffer, layered underneath with NB3 buffer, and nuclei were pelleted through the 
sucrose step gradient. After discarding the supernatant, nuclei were resuspended in EB buffer, 
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homogenized with a type B dounce homogenizer, and rotated for 30 minutes at 4ºC. After 
pelleting the nuclear debris, the supernatant containing nuclear proteins was dialyzed overnight 
in Z buffer. Protein concentration for all lysates was determined by protein assay (Bio-Rad), and 
normalized protein samples were resolved in 10% or 15% SDS-PAGE gels after boiling at 100ºC 
for 5 minutes in 6X SDS sample buffer. Proteins were then transferred to nitrocellulose 
membranes in a semi-dry transfer apparatus (Bio-Rad). Proteins of interest were probed by 
indicated antibodies and detected by chemiluminescence. Densitometry measurements of protein 
bands were performed in ImageMeter (Flashscript).  
 
2.5.6 Immunofluorescence 
 After induction of AR expression and serum starvation, PC12 cells were washed in PBS 
and fixed in 4% paraformaldehyde. Proximal hind limb muscles were collected for 
cryosectioning from mice after the indicated treatments and perfusion with 4% 
paraformaldehyde. After perfusion, muscles were further fixed in 4% paraformaldehyde 
overnight, 15% sucrose for 4 hours, 30% sucrose overnight, then flash frozen in liquid nitrogen 
and mounted in cryosection blocks with OCT Compound (Tissue-Tek). Sections were then cut at 
10µm using a Cryocut 1800 cryostat (Leica). Cells and muscle sections were stained with 
indicated antibodies and mounted with Vectashield medium with DAPI (Vector Labs). 
Fluorescence images were taken with a Zeiss Axio Imager microscope. GFPLC3 puncta were 
quantified in ImageJ (NIH) using a GFP-LC3 quantification macro designed by Dagda and Chu 
[219, 251]. 
 
2.5.7 Statistics 
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 Statistical significance was determined by ANOVA with Newman Keuls multiple 
comparison test or unpaired two-tailed Student’s t-test using Prism 6 (GraphPad). Differences 
were considered significant when P values were less than 0.05. 
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Chapter 32 
 
Disruption of polyglutamine androgen receptor SUMOylation rescues skeletal 
muscle function and ameliorates the phenotype of SBMA mice 
 
3.1 Abstract 
Expansion of the androgen receptor’s (AR) polyglutamine (polyQ) tract, the cause of 
neurodegeneration in spinobulbar muscular atrophy (SBMA), diminishes AR-mediated 
transactivation and confers ligand-dependent toxicity. While both of these effects are implicated 
in SBMA, the extent to which altered AR function contributes to pathogenesis remains 
controversial. Here we manipulated AR function by mutating conserved lysines that are targeted 
by SUMO, a modification that inhibits AR transactivation. We show that replacement of these 
residues by arginine enhances polyQ AR activity as a hormone-dependent transcriptional 
regulator. We use gene targeting to generate mice expressing the polyQ AR in which these 
SUMOylation sites are similarly disrupted. Inhibition of polyQ AR SUMOylation rescues 
deficits in exercise endurance and Type I muscle fiber atrophy and prevents early death. These 
changes occur independent of effects on polyQ AR expression or aggregation, but instead reflect 
beneficial, trophic support by the ligand-activated receptor. Unexpectedly, disruption of the 
androgen axis in mutant males is largely unaffected by abrogating AR SUMOylation, suggesting 
                                                        
2 This chapter is in preparation for submission for publication. 
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that features of the disease previously attributed to partial loss of receptor function may, in fact, 
reflect polyQ-mediated toxicity in peripheral tissues. Our findings demonstrate beneficial effects 
of the ligand-activated polyQ AR and indicate that the SUMOylation pathway may provide new 
targets for therapeutic intervention. 
 
3.2 Introduction  
Modulation of androgen receptor (AR) function leads to profound effects on 
transcriptional programming, tissue physiology and disease progression. Stimulation of AR 
function not only effects development of the masculine sexual phenotype, motor neuron survival 
and skeletal muscle anabolism [252-257], but enhanced AR function also exacerbates certain 
diseases such as prostate cancer [52, 55-62]; conversely, diminution or antagonism of AR 
function improves prostate cancer outcomes [258-260] and underlies androgen insensitivity 
syndromes [261, 262]. Consequences of altered AR function are particularly relevant for 
spinobulbar muscular atrophy (SBMA), a heritable, progressive neurodegenerative disorder 
belonging to the family of nine polyglutamine (polyQ) diseases characterized by pathologic 
expansions of CAG repeats [13]. The mutation in SBMA occurs in exon 1 of the AR gene and 
confers a hormone-dependent toxic gain of function to the polyQ AR that precipitates cell death 
of lower motor neurons and atrophy of skeletal muscle [1, 263]. In addition, expansion of the 
AR’s polyQ tract results in a partial loss of transactivation function and correlates with 
symptoms of androgen insensitivity in SBMA patients [6]. Although these aspects of altered 
polyQ AR physiology have been well-characterized, the degree to which impairment in AR 
function contributes to SBMA is not fully understood. 
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 Of the cell types undergoing degeneration in SBMA, both lower motor neurons and 
skeletal muscle express the polyQ AR and exhibit trophic responses following activation of the 
wild type receptor. Motor neuron death has been thought to underlie neurogenic atrophy in 
SBMA muscle and the lower motor neuron signs in SBMA patients [2, 4], yet elevated serum 
creatine kinase levels and mixed histopathologic changes in muscle biopsies suggest that the 
disease is, in part, a primary myopathy [10]. Further evidence in support of an essential role of 
muscle-autonomous toxicity in pathogenesis derives from studies in which muscle-specific 
overexpression of wild type AR recapitulates numerous features of SBMA [155, 160]. The 
polyQ AR has also been shown to compromise mitochondrial function and repress PGC-1 
expression, both of which are critical mediators of muscle homeostasis [151]. Indeed, we have 
previously shown in AR113Q knock-in mice that muscle pathology occurs prior to signs of 
pathologic change in spinal cord [101], and this occurs concomitant to transcriptional alterations 
deleterious to muscle [150, 264]. Consistent with these studies, muscle-specific interventions 
significantly influence disease severity. Inhibition of the unfolded protein response exacerbates 
muscle pathology and worsens disease, while muscle-specific overexpression of IGF-1 rescues 
SBMA phenotype [152, 158]. Furthermore, suppression of polyQ AR expression only in 
peripheral tissues by antisense oligonucleotides is sufficient to rescue skeletal muscle atrophy 
and prevent early death in AR113Q mice [265]. These studies highlight the importance of 
skeletal muscle in SBMA pathogenesis, yet leave unresolved the extent to which alterations in 
normal AR function contribute to disease. 
 Endogenous mechanisms regulating AR function act by dint of posttranslational 
modifications. One such covalent linkage is the enzymatic addition of small ubiquitin-like 
modifier (SUMO). SUMO shares a large degree of sequence identity with ubiquitin, and both 
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peptides similarly attach to target substrates via isopeptide bonds on the terminal -amino group 
of lysine residues [190, 266-268]. Additionally, both proteins share analogous processing, 
conjugation, and ligation steps using E1, E2, and E3 enzymes [196-200]. The functional 
consequence of SUMOylation on modified substrates is modulation of protein activity or 
intracellular re-localization in response to cellular conditions and stress stimuli [188, 201, 269]. 
Furthermore, SUMOylation is a transient modification due to recurrent deconjugation of the 
SUMO moiety by SUMO proteases, rendering the steady state proportion of SUMOylated 
substrates a relatively small fraction of overall protein population [206]. Of the three SUMO 
paralogues expressed by mammals, AR is primarily modified by SUMO1 [63]. Conjugation by 
this SUMO isoform, which does not form polySUMO chains, occurs preferentially on lysine 
residues 385 and 518, which fall within consensus SUMOylation sites encoded by amino acids 
IK
385
LE and VK
518
SE, conserved motifs previously defined as transcriptional regulatory 
sequences in nuclear receptors [63, 217].  
SUMOylation has attracted considerable attention for its impact on neurodegenerative 
diseases. Several mutant proteins that cause neurodegeneration are targets of SUMOylation, and 
the extent to which SUMO influences disease pathogenesis varies in a context-dependent manner 
[69, 207-216, 270]. For the AR, transactivation function is significantly repressed upon 
modification by SUMO. This repression is markedly promoter-context dependent [217], is 
associated with a shift of nuclear localized AR away from chromatin binding [63, 217, 271], and 
is alleviated by mutating the two consensus SUMO-acceptor lysines to arginines [63, 217]. Here 
we test the hypothesis that changes in polyQ AR SUMOylation will improve components of 
SBMA stemming from altered AR function. Our approach is based on the established effects of 
SUMO on AR-dependent gene expression, the significant loss of transactivation caused by 
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polyglutamine expansion, and prior studies suggesting that AR function contributes to SBMA 
pathogenesis [47, 89, 264]. To accomplish this, we used gene targeting to generate a novel 
knock-in mouse line that expresses a non-SUMOylatable, polyglutamine-expanded AR. Our 
studies characterizing this new mouse model of SBMA, complemented by additional 
experimental systems in vitro, provide a unique avenue to examine the effects of disinhibiting 
AR function and disentangling the pathogenic role of AR dysfunction from polyQ toxicity in 
vivo. 
 
3.3 Results 
 
3.3.1 Establishment of a cellular model expressing non-SUMOylatable polyQ AR 
 To initially study the effects of abrogating SUMOylation of the polyQ AR, we used PC12 
cells expressing tetracycline-regulated AR10Q, AR112Q, and AR112Q with its SUMO-acceptor 
lysines mutated to arginines, AR112Q-KRKR (Fig. 3.1A). With these cells, we tested whether 
introducing mutations that prevent SUMOylation affected the response of AR112Q to ligand. In 
the absence of the synthetic non-aromatizable androgen R1881, all three variants of AR 
displayed a predominantly cytoplasmic distribution, in agreement with expected localization 
when unbound to ligand (Fig. 3.1B, left column). With addition of R1881, all three cell lines 
demonstrated similar nuclear redistribution of AR, and both AR112Q and AR112Q-KRKR 
similarly formed intranuclear aggregates (Fig.3.2B, right column and arrows). To verify that 
the KRKR mutations interrupt AR SUMOylation, we transiently transfected AR112Q and 
AR112Q-KRKR cells with hemagglutinin (HA)-tagged SUMO3, then immunoprecipitated each 
AR112Q variant and probed for HA. Western analysis confirms that the KRKR mutation  
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Figure 3.1 A cellular model expressing non-SUMOylatable polyQ AR 
(A) AR10Q, AR112Q, or AR112Q-KRKR were expressed in the presence or absence of 10nM 
R1881 for 24 hours. (B) AR10Q, AR112Q, and AR112Q-KRKR cells were induced as in (A) 
and immunostained for AR (red). Nuclei were stained by DAPI. Arrows indicate nuclei 
containing aggregates. Scale bar, 2μm. (C) AR112Q and AR112Q-KRKR cells were transfected 
with HA-SUMO3. Whole cell lysates were immunoprecipitated for AR and probed for HA.  
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prevents AR modification by SUMO (Fig. 3.1C). We therefore conclude that our PC12 cell 
model abolishes SUMO modification of AR112Q without significantly altering ligand-dependent 
localization of the polyQ receptor. 
 
3.3.2 Abrogating SUMOylation enhances transactivation activity of polyQ AR  
 To examine the effects of the KRKR mutation on transactivation function, we prepared 
cDNA from cells expressing AR10Q, AR112Q or AR12Q-KRKR following stimulation with 
R1881 or control. These samples were analyzed by Affymatrix GeneChip microarrays, and the 
results were plotted in a heatmap of genes significantly activated (in red) or repressed (in blue) 
by androgen (Fig. 3.2A and B) and displayed as a Venn diagram of androgen-responsive genes 
(Fig. 3.2C). This analysis confirmed a glutamine-length dependent partial loss of AR function 
(Fig. 3.2A). Of the 93 ligand-responsive genes identified in cells expressing AR10Q, only 32 
were ligand-regulated by AR112Q and 49 by AR112Q-KRKR. We verified one such gene 
(Ppard) that was androgen-responsive to all three AR variants by quantitative real-time RT-PCR 
(qPCR) (Fig. 3.2D). To verify the glutamine length-dependence of androgen-responsiveness, we 
performed qPCR analysis on two separate genes identified by microarray and found significantly 
lower expression changes produced by ligand activation of AR112Q compared to AR10Q (Fig. 
3.2D). These data are in line with expectations that the expanded glutamine tract reduces AR 
activity as a transcriptional regulator [31-36, 69]. Intriguingly, we also found that the KRKR 
mutation enabled the polyQ AR to activate a markedly larger set of genes. In contrast to the 93 
genes regulated by AR10Q, AR112Q-KRKR altered the expression of 246 genes, 197 of which 
fell below threshold for ligand responsiveness to AR10Q, and 183 of which were below 
threshold for responsiveness to both AR10Q and AR112Q (Fig. 3.2B and C). This robust, 
ligand-dependent regulation of gene expression by AR112Q-KRKR was confirmed by qPCR. In  
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Figure 3.2 Disruption of polyQ AR SUMOylation potentiates AR function. 
(A) Heatmap showing expression of genes activated (red) or repressed (blue) 1.5-fold or greater 
by AR10Q cells compared to expression in AR112Q and AR112Q-KRKR cells. (B) Heatmap 
comparing expression of 183 androgen-responsive genes unique to AR112Q-KRKR cells to 
expression of those genes in AR10Q and AR112Q cells. (C) Venn diagram illustrating the 
number and overlap of androgen-responsive genes in AR10Q (black circle), AR112Q (blue 
circle), and AR112Q-KRKR cells  (red circle). (D) Candidate genes that show relative 
transactivation function (Ppard, Baiap2, and Chst1 in black, red, and purple, respectively) in 
AR112Q-KRKR cells were identified in (A) and analyzed by qPCR. Data shown are mean +/- 
SEM (n=3). ****p<0.0001. 
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contrast to the reduced expression observed in response to AR112Q, ligand activation of 
AR112Q-KRKR triggered significantly higher gene expression than both AR112Q and AR10Q 
in a promoter context-dependent manner (Fig. 3.2.D). These results are consistent with previous 
mechanistic data [69, 217] and demonstrate that, although expansion of the glutamine tract 
diminishes activation of genes normally induced by AR, preventing SUMOylation through the 
KRKR mutation enhances polyQ AR transactivation capacity and expands the number of ligand-
responsive genes. 
 
3.3.3 Generation of AR113Q-KRKR knock-in mice 
 To investigate the influence of SUMOylation in vivo, we used gene targeting to generate 
a new knock-in mouse model of SBMA that expresses the polyQ AR with K385 and K518 both 
mutated to arginines. We modified the targeting vector used previously to generate our existing 
AR113Q line of knock-in mice by introducing the KRKR mutations (Fig. 3.3A). We verified 
correct recombination of the targeted exon 1 into the mouse Ar gene by Southern analysis in 
JM8.F6 cells, an embryonic stem cell line from the C57BL/6N strain (Fig. 3.3B). After germline 
transmission of the targeted allele from chimeric founders to F1 heterozygous females, we 
crossed these females to C57BL/6J wild type males and assessed subsequent inheritance of the 
AR113Q-KRKR allele by PCR (Fig. 3.3C). For the purposes of phenotypic characterization in 
this study, we used AR113Q male mice backcrossed >ten generations on the C57BL/6J 
background, N1 AR113Q-KRKR male mice, and wild type littermate males from both lines. 
Females from both 113Q lines were similarly fertile and both AR113Q alleles were inherited in 
the expected Mendalian ratios (data not shown). Both lines of male mice were indistinguishable 
prior to disease onset at sexual maturity. 
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3.3.4 AR113Q-KRKR males demonstrate partial androgen compromise 
 Since partial loss of AR function and features of androgen insensitivity are molecular and 
phenotypic hallmarks of SBMA, we examined several measures of androgen function on the 
hypothalamic-pituitary-gonadal (HPG) axis in AR113Q-KRKR mice. Compared to wild type 
mice, both AR113Q and AR113Q-KRKR mice demonstrated testicular and seminal vesicle  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Generation of AR113Q-KRKR knock-in mice. 
(A) Schematic representation depicting AR113Q-KRKR targeting vector. SphI restriction sites, 
5’ and 3’ probes for Southern analysis, glutamine tract, lysine to arginine mutations, and floxed 
neomycin resistance cassette are indicated. Diagram modified from [272]. (B) Southern analysis 
of ES cell DNA after SphI digestion with the 5’ and 3’ probes indicated in (A) before (lanes 1 
and 4) and after (lanes 2 and 5) homologous recombination. Lanes 3 and 6 contain control liver 
DNA from previously targeted AR113Q knock-in line. L, ladder. (C) PCR primers that span the 
CAG tract were used to amplify sequences from a wild type female (lane 1), F1 AR113Q-KRKR 
female (lane 2), and N1 AR113Q-KRKR male produced by the female in lane 2. 
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atrophy and reduced sperm count (Fig. 3.4A). Modest elevations in serum testosterone and 
luteinizing hormone were evident in both AR113Q and AR113Q-KRKR males, but because of 
variability between animals these changes did not reach statistical significance (Fig. 3.4B). We 
also analyzed testicular expression of 3--hydroxysteroid dehydrogenase type I (3HSD-I), an 
enzyme responsible for keto-steroid hormone synthesis in Leydig cells in response to LH and 
whose expression is indicative of androgen insensitivity [273]. Consistent with the endocrine 
tissue pathology and serum studies, we found similar increases in 3HSD-I mRNA in testes from 
both 113Q lines of mice (Fig. 3.4C). These data demonstrate that glutamine length-dependent 
partial loss of AR function occurs independent of SUMOylation status, and suggest that toxicity 
stemming from polyglutamine expansion provides determinative influence on endocrine 
compromise in SBMA mice. 
 
3.3.5 Behavioral and neuromuscular phenotypes in AR113Q-KRKR mice 
 As the phenotype of AR113Q mice includes decreased body mass and grip strength, we 
also evaluated these parameters in AR113Q-KRKR mice and found indistinguishable deficits 
(Fig. 3.5A, B). The reduction in these measures became evident ~12 weeks and persisted 
thereafter. To broaden our characterization of muscle function beyond assessment of grip 
strength, we examined exercise capacity by treadmill running until exhaustion. By this measure 
we detected a significant decrement in exercise endurance in AR113Q mice, consistent with 
other measures of functional decline [101, 274-276] in SBMA muscle (Fig. 3.5C). Strikingly, 
KRKR mutations in polyQ AR yielded a profound rescue of exercise capacity to levels 
equivalent to wild type mice. This functional rescue persisted in mice aged up to 9 months (Fig.  
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Figure 3.4 Characterization of the hypothalamic-pituitary-gonadal axis in AR113Q-
KRKR mice. (A) Testes and seminal vesicles were collected at 13-15 weeks and analyzed by 
weight (left and middle panels). Epididymes were collected and sperm count determined (right 
panel). Data are shown as mean +/- SEM (n=6 per group). *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. (B) Serum samples (n=6 per group) were collected at 13-15 weeks and analyzed 
for levels of testosterone (T) and leutinizing hormone (LH). Data shown as mean +/- SEM. (C) 
Total RNA was extracted from testes from WT, AR113Q, and AR113Q-KRKR mice (n=3 per 
group) at 13-15 weeks and analyzed for 3HSD-I expression by qPCR. Data are shown as mean 
+/- SEM. ****p<0.0001. 
 
3.5D). We hypothesized that this recovery in KRKR mutants could reflect either diminished 
ligand-dependent toxicity from the expanded glutamine tract or increase trophic support by the 
ligand-activated receptor. To distinguish between these possibilities, we applied the same 
exercise paradigm to AR113Q-KRKR males that had been castrated at 5-6 weeks and to wild 
type females. Exercise trials of these two cohorts revealed substantially less exercise capacity 
compared to gonadally intact males regardless of glutamine tract length. These results confirmed 
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the supportive role of androgens in the development of exercise endurance and in directing the 
exercise rescue in SUMO-resistant SMBA mice. 
 Since early death is another pathognomonic feature of AR113Q mice, we followed 
cohorts of wild type, AR113Q, and AR113Q-KRKR mice and monitored survival rates. In line 
with previous characterization [101], AR113Q mice demonstrated a precipitous decline in 
survival beginning at 13 weeks (Fig. 3.5E, left). None of these mice survived past 40 weeks (n = 
10). In contrast, AR113Q-KRKR mice exhibited a profound extension of lifespan. Through 40 
weeks, only one death occurred in the experimental cohort (n = 10). This rescue of early death 
was significant (p<0.0001) and took place despite a lack of discernable differences in disease 
onset (p=0.6) between the SUMOylatable and non-SUMOylatable AR113Q lines (Fig. 3.5E, 
middle). Accordingly, the equivalent disease onset coupled with lifespan extension resulted in a 
significant extension of disease duration (p=0.02) in the SUMOylation-deficient SBMA mice 
(Fig. 3.5E, right). Taken together, these results uncovered profound beneficial consequences of 
abrogating SUMOylation and, in turn, potentiating AR function on exercise endurance and 
disease progression.  
  
3.2.6 Rescue of Type I muscle fiber atrophy in AR113Q-KRKR mice 
 To understand the mechanism underlying phenotypic rescue in AR113Q-KRKR mice, we 
initially sought to determine whether mutant forms of the AR were similarly expressed. 
Immunoprecipitation of AR from quadriceps muscle and spinal cord demonstrated that levels of 
AR113Q-KRKR were similar to or slightly higher than wild type and AR113Q protein (Fig. 
3.6A). Similarly, qPCR showed similar levels of AR mRNA in quadriceps muscle from all three 
mouse lines (Fig. 3.6D). Since AR113Q mice display frequent accumulation of intranuclear  
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Figure 3.5 Phenotypic characterization of AR113Q-KRKR knock-in mice. (A) Wild 
type, AR113Q, and AR113Q-KRKR male mice (n=10 per group) were weighed and (B) assessed 
for forelimb grip strength every two weeks. Data shown are mean +/- SEM. (C) Wild type (n=7), 
AR113Q (n=6), AR113Q-KRKR male mice (n=6), castrated AR113Q-KRKR males (AR113Q-
KRKR-C, n=4) and wild type females (n=4) were exercised until exhaustion at 13-15 weeks of 
age, and total time and distance run were recorded. Data are mean +/- SEM. *p<0.05, **p<0.01. 
(D) Wild type, 113Q, and 113Q-KRKR (n=3 per group) males were exercised until exhaustion at 
7-9 months of age, and total time and distance run were recorded. Data are mean +/- SEM. 
*p<0.05. (E) Wild type, AR113Q, and AR113Q-KRKR male mice (n=10 per group) were 
followed for overall survival (left panel, p<0.0001 113Q vs. 113Q-KRKR by Mantel-Cox log-
rank test), and both 113Q knock-in mouse lines were monitored for disease onset (middle, 
p=0.06), and disease duration (right, p=0.02).  
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aggregates of polyQ AR in skeletal muscle [277], we analyzed sections of levator 
ani/bulbocavernosus (LABC) and quadriceps muscle from mice aged 13-15 weeks. While nuclei 
in wild type muscle rarely showed punctate AR intranuclear staining (5.5±2.3%), nuclei from 
both AR113Q and AR113Q-KRKR muscle showed substantially higher and similar amounts of 
polyQ AR aggregates (26.9±2.2% and 29.4±1.9%, respectively) (Fig. 3.6B). These analyses 
indicated that phenotypic rescue was not attributable to altered levels of polyQ AR expression or 
aggregation. Furthermore, rescue was not associated with attenuation of muscle atrophy or 
skeletal muscle gene expression changes indicative of denervation. The tibialis anterior (TA) 
muscle showed significant atrophy in both AR113Q and AR113Q-KRKR mice compared to wild 
type (Fig. 3.6C), and both AR113Q lines exhibited increased expression of acetylcholine 
receptor- subunit and myogenin mRNAs in quadriceps muscle, with a similar trend observed 
for the expression of MyoD mRNA (Fig. 3.6D). Unexpectedly, these measurements of muscle 
pathology were accentuated in AR113Q-KRKR mice despite rescue of exercise capacity and 
survival.  
To address the discrepancy between muscle pathology and physiology, we evaluated 
fiber typing in soleus muscle. Fiber type properties and distribution greatly influence exercise 
performance and metabolic profiling, since Type I (slow twitch) fibers are rich in mitochondria, 
fatigue-resistant, and reliant on oxidative metabolism, while Type II (fast twitch) fibers are 
mitochondria-poor, fatigue-susceptible, and dependent on glycolytic metabolism [278-281]. We 
performed fiber type-specific immunostaining for slow twitch heavy chain myosin on soleus 
muscle given its mixed fiber type composition; in contrast, both the TA and quadriceps muscles 
that were previously analyzed are Type II fiber predominant [282-284]. We observed atrophy  
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Figure 3.6 AR113Q-KRKR mice demonstrate fiber type-specific atrophy (A) AR 
expression in quadriceps and spinal cord from WT (lanes 1 and 2), AR113Q (lanes 3 and 4) and 
AR113Q-KRKR mice (lanes 5 and 6). (B) Immunofluorescent staining for AR (red) in 
quadriceps and LABC. Nuclei were stained by DAPI (blue). Scale bar, 25µm. Data are mean +/- 
SEM. ****p<0.0001. (C) Tibialis anterior (TA) muscle was weighed (n=6 per group). Data are 
mean+/- SEM. **p<0.01, ****p<0.0001. (D) AR (Ar), nicotinic acetylcholine receptor  subunit 
(Chrna1), myogenin (Myog), and MyoD (Myod) mRNA were analyzed in quadriceps by qPCR 
(n=6 per group). *p<0.05, ***p<0.001, ****p<0.0001. (E) Representative Type I slow twitch 
heavy chain myosin (green) and Type II fast twitch heavy chain myosin (red) staining in soleus. 
Basement membrane stained with wheat germ agglutinin (green). Scale bar, 50µm. (F) Mean 
area+/- SEM and fiber size distribution of each fiber type (n=3 mice per group, ≥75 fibers per 
mouse). **p<0.01, ****p<0.0001.  
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across all fiber types in AR113Q soleus muscle (Fig. 3.6E, top middle). In contrast, Type I 
fibers in soleus from AR113-KRKR mice were remarkably spared from atrophy (Fig. 3.6E top 
right). Quantification of cross-sectional area demonstrated a significant rescue in the distribution 
and mean Type I fiber size (Fig. 3.6F). This rescue of muscle atrophy was not seen in Type II 
fibers of AR113Q-KRKR muscle, nor was it observed in Type I fibers of AR113Q-KRKR mice 
following castration (Fig. 3.6F). These data indicate that disruption of AR113Q SUMOylation 
interrupts myotoxic insults brought about by the polyglutamine expansion and promotes 
hormone-dependent trophic protection of Type I oxidative fibers to strengthen exercise capacity. 
 
3.4 Discussion  
 Expansion of the AR’s polyQ tract significantly modifies the receptor’s activity as a 
ligand-activated transcriptional regulator, and effects on native function of the AR have been 
postulated to contribute to aspects of SBMA pathogenesis [89, 90]. In this study, we sought to 
disentangle alterations in the receptor’s normal function from polyQ length-dependent 
proteotoxicity to discern the relative contributions of each pathogenic mechanism to disease 
development. To accomplish this goal, we mutated lysine residues in AR exon 1 that fall within 
consensus SUMOylation sites. We show that the non-SUMOylatable polyQ AR responds as 
expected to ligand activation, as evidenced by nuclear translocation and the formation of 
intranuclear inclusions. The ligand-activated AR112Q-KRKR regulates the expression of an 
expanded set of target genes compared with the wild type or AR112Q receptors, consistent with 
the established repressive role of SUMOylation on AR function. Male mice generated by gene 
targeting to express AR113Q-KRKR develop normally and express a phenotype only after 
reaching sexual maturity. Intriguingly, these mice exhibit a significant recovery of exercise 
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capacity compared with AR113Q males. This rescue persists even into old age despite 
decrements in exercise fitness across all genotypes. Moreover, this rescue is hormone-dependent 
and is associated with recovery of Type I muscle fiber atrophy, demonstrating that ligand-
dependent activation of AR113Q-KRKR provides significant trophic support to muscle. These 
effects are also associated with an almost complete rescue of early death and a marked extension 
of disease duration. As the phenotypic rescue of AR113Q-KRKR males occurs without evidence 
of diminished polyQ AR expression or aggregation and is hormone-dependent, we conclude that 
the beneficial effects of abrogating SUMOylation are mediated by enhanced native function of 
the receptor. Notably, these conclusions are distinct from those drawn from an analysis of a 
Drosophila model of SBMA in which native function of the AR was implicated in pathogenesis 
[89]. However, as Drosophila lack androgen responsive genes, it is likely that this prior screen 
identified factors that regulate cellular fitness in the presence of an expanded polyQ tract but was 
insensitive to trophic actions mediated by the ligand-activated receptor. 
 Not all aspects of the phenotype of AR113Q males are rescued in AR113Q-KRKR 
mutants. Disruption of SUMOylation fails to significantly modify certain aspects of muscle 
pathology, including weight of muscles that are primarily composed of Type II fibers, grip 
strength (a phenotype that may reflect activity of fast twitch fibers), and gene expression changes 
indicative of denervation. The discrepancy in fiber type composition likely reflects a greater 
response to trophic support by the SUMOylation-resistant receptor in Type I muscle fibers. 
Though these slow twitch fibers account for only a small fraction of overall skeletal muscle mass 
in mice, they are much more abundant in humans [285, 286], suggesting that strategies to target 
AR SUMOylation may have greater beneficial effects in SBMA patients. Unexpectedly, 
endocrine pathology, including seminal vesicle and testicular atrophy, sperm count, and 3HSD-
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I mRNA expression are also unaffected by AR SUMOylation. These findings indicate that 
toxicity in the hypothalamic-pituitary-gonadal axis is arises in part from proteotoxicity of the 
polyQ tract acting in peripheral tissues, a finding in accordance with our earlier analysis of 
AR113Q mice [107]. 
Prior studies have suggested a modulatory role for SUMO in models of SBMA, though 
their findings are not in complete concordance with the analysis of AR113Q-KRKR mice. In a 
Drosophila model of SBMA, the degenerative phenotype is worsened by a C177S loss of 
function mutation in Uba2, an essential component of the E1 SUMOylation complex [138]. 
These findings suggest that global impairment of the SUMO pathway may be detrimental in 
disease, a strategy that is distinct from the genetic approach of specifically modulating AR 
SUMOylation used in these studies. Additionally, aggregates and high molecular weight 
oligomers of the polyQ AR, which are thought to confer the toxic gain of function of the mutant 
protein, are substantially reduced upon overexpression of SUMO3 in cell culture [69].  
We suspect that our data are not inconsistent with those findings since the protective 
effects on aggregation were observed only in the setting of SUMO3 overexpression, and 
introducing the KRKR mutations in the same cell model did not exacerbate AR aggregation [69]. 
In this study, we confirmed this observation in vivo and did not enhance polyQ AR aggregation 
in mice by mutating SUMO acceptor sites (Fig. 3.6B). These results may reflect the fact that 
endogenous modification of AR occurs predominantly by SUMO1 [63], an isoform that is unable 
to form polySUMO chains and therefore less likely to influence target protein solubility. In 
addition, the effects of SUMO3 overexpression are likely reflective of acute stress conditions, 
whereas in vivo the long-term SUMOylated fraction of the total pool of AR under physiological 
conditions is relatively small due to dynamic deconjugation by SUMO proteases [63, 206, 269]. 
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Nevertheless, our novel AR113Q-KRKR mice have yielded important insights into modulating 
AR function in vivo and the resultant effects on phenotypic measures of SBMA. Overall, our 
new knock-in model significantly advances our understanding of SBMA pathogenesis and 
provides new routes of investigation into molecular aspects of the polyQ AR. 
 
3.5 Materials and Methods 
 
3.5.1 Antibodies 
 Primary antibodies used for Western analysis were against AR (N-20, Santa Cruz), 
Hsp90 (Santa Cruz), and HA (Covance). Primary antibodies for immunofluorescence were 
against AR (N-20, Santa Cruz), Type I/slow twitch heavy chain myosin (A4.840, DSHB, 
University of Iowa), and Type II/fast twitch heavy chain myosin (Ab-2, Thermo Scientific). 
Horseradish peroxidase-conjugated secondary antibodies used for Western analysis were from 
Bio-Rad. AlexaFluor 594, AlexaFluor 488, and wheat germ agglutinin AlexaFluor 488 conjugate 
antibodies used for immunofluorescence were from Invitrogen. FITC-conjugated donkey anti-
mouse IgM was from Jackson ImmunoResearch. For immunoprecipitation experiments, the anti-
AR antibody PG-21 (Millipore) was used, and pulldown was performed with Protein A-agarose 
beads (Santa Cruz).  
 
3.5.2 Cell culture, Western blot and immunoprecipitation 
 PC12 cells expressing tetracycline-regulated AR10Q and AR112Q have been described 
previously [97]. Tet-ON AR112Q-KRKR cells were kindly provided by Diane Merry (Thomas 
Jefferson University). Induction of AR expression in AR10Q, AR112Q, and AR112Q-KRKR 
cells to equivalent protein levels was performed with 50ng/mL, 3ng/mL, and 500ng/mL 
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doxycycline (Clontech), respectively, in the presence of 10nM R1881 or ethanol vehicle for 24h 
unless otherwise indicated. Cells were grown and passaged on poly-D-lysine-coated flasks in 
high glucose phenol-red free Dulbecco’s modified Eagle’s medium (Invitrogen) containing 15% 
charcoal-stripped horse serum (Invitrogen), 10% charcoal-stripped fetal bovine serum (Thermo 
Scientific), 100 units/mL penicillin/streptomycin (Invitrogen), 200µg/mL hygromycin B 
(Invitrogen), and 100 µg/mL G418 (Invitrogen) at 37ºC in 15% CO2. For Western analysis, cells 
were washed twice and collected by cell scraper in PBS, then lysed in RIPA buffer supplemented 
with Halt phosphatase inhibitors (Thermo Scientific), c0mplete protease inhibitors (Roche), and 
20mM N-ethylmaleimide (Sigma) to irreversibly inhibit SUMO proteases. Whole cell lysates 
were pre-clarified by centrifugation at 15,000 x g for 15 minutes at 4ºC. Protein concentrations 
were determined by modified protein assay (Bio-Rad). After boiling at 100ºC for 5 minutes in 
loading buffer, all protein samples were resolved on 7% or 10% SDS-PAGE gels, transferred to 
nitrocellulose membranes on a semi-dry transfer apparatus (Bio-Rad), and probed by the 
indicated antibodies. Detection was performed by chemiluminescence. For immunoprecipitation, 
protein lysates were diluted to 500µg of protein for PC12 cells or 1500µg for mouse tissues in 
500µL of RIPA buffer and incubated with 10µg of PG-21 antibody overnight at 4ºC rotating. 
Protein A-agarose beads were pre-washed 3 times in RIPA, then incubated in 
immunoprecipitation samples for 1 hour at 4ºC rotating. Bead-antibody complexes were then 
centrifuged in filtered spin columns (Thermo Scientific), washed 4 times in lysis buffer, and 
eluted by boiling in loading buffer for 5 minutes at 100ºC. 
 
3.5.3 Transient transfection 
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 Transfection of pcDNA3-HA-SUMO3 was performed with Amaxa Nucleofector (Lonza) 
according to manufacturer’s instructions. Cells were collected at 2 x 106 cells per sample and 
electroporated with 2µg of plasmid, then plated on poly-D-lysine-coated 60mm dishes (BD 
Falcon). Medium was changed 3 hours later after cell attachment and replaced with normal 
growth medium containing doxycycline and R1881.  
 
3.5.4 Generation of knock-in mice 
 Knock-in mice with AR allele containing 113 CAG repeats were derived using gene 
targeting as described previously [107, 272]. To generate AR113Q-KRKR mice, this strategy 
was modifed by using using the previously described AR113Q targeting vector as template. 
Briefly, a portion of p5HB-hAR24Q-KRKR containing the K385R and K518R mutations was 
excised as an NruI/XhoI fragment and cloned into pLP1-AR113Q. The codons for K385 and 
K518 were AAG and AAA, respectively, and were mutated to codons for arginine AGA and 
CGA, respectively. Both K to R mutations and the CAG repeat tract length were verified by 
sequencing. The modified targeting construct containing amino acids 31-484 of human AR exon 
1 and K385,518R mutations replaced mouse AR exon 1 by homologous recombination in 
JM8.F6 embryonic stem cells. Correct targeting of the AR113Q-KRKR allele was verified 
through Southern blot analysis using 5’ and 3’ probes falling outside of the targeted construct 
(Fig. 3.2A). Three clones of correctly targeted ES cells were selected by neomycin resistance, 
karyotyped to verify euploidy, transiently transfected with Cre recombinase to excise the floxed 
neomycin resistance cassette, and injected into C57BL/6J blastocysts obtained from mating 
C57BL/6-BrdCr-Hsd-Tyrc females with C57BL/6-BrdCrHsd-Tyrc males. These blastocysts 
 68 
were then implanted in pseudopregnant C57BL/6J females. All ES cell procedures were 
performed by the University of Michigan Transgenic Animal Model Core. 
 
3.5.5 Mouse breeding and care 
 ES cell implantations yielded eight chimeric males in total, which were then mated with 
albino C57BL/6J females (Jackson Laboratory) to sire AR113Q-KRKR F1 female mice 
heterozygous for the targeted allele. Germline transmission of the targeted AR allele was 
indicated by black coat color and confirmed by PCR genotyping. These females were bred to 
C57BL/6J wild type males to generate AR113Q-KRKR males for use in this study and AR113Q-
KRKR heterozygous females to maintain the line. Mice were group housed in an SPF facility 
and provided with chow and water ad libitum. Genotypes were verified by PCR of DNA 
harvested from tail biopsies obtained shortly after weaning, using the forward primer 5’-
CCAGAATCTGTTCCAGAGCGTG-3’ and the reverse primers 5’-
TGTTCCCCTGGACTCAGATG-3’ and 5’-GCACTCCAGGGCCGACTGCG-3’ in a 2:2:1 
ratio, respectively.    
 
3.5.6 Mouse phenotyping and tissue collection 
 Every two weeks beginning at 8 weeks of age, male mice were weighed and forelimb 
strength was measured by grip strength meter (Columbus Instruments). Following acclimation to 
the instrument, mice were allowed to grip the triangular pull bar with forelimbs only and were 
then pulled backward horizontally, and the average peak tension value from five consecutive grip 
trials was reported as the grip strength for each mouse. Disease onset was defined as the age at 
which grip strength was 10% less than the mean of age-matched controls. Skeletal muscles 
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(quadriceps, gastrocnemius, soleus, tibialis anterior, levator ani-bulbocavernosus), spinal cord, 
testis, and seminal vesicles were collected from adult males 13 to 15 weeks old and weighed or 
flash frozen in liquid nitrogen for biochemical analysis or mounted on OCT blocks for 
cryosectioning. Epididymes were also collected at this time, minced in 4mL of PBS, incubated 
for 10 minutes at room temperature with gentle agitation, centrifuged for 1 minute at 500 x g, 
and applied to a hemacytometer to determine sperm counts. For tissue analyses, quadriceps 
muscle and lumbar spinal cord were minced, lysed by agitation at 4ºC for 1 hour, and 
homogenized in RIPA buffer containing phosphatase and protease inhibitors. Tissue lysates were 
then clarified at 13,000 x g for 10 minutes at 4ºC. Protein concentrations were determined by 
modified protein assay (Bio-Rad). 
 
3.5.7 Measurement of serum hormone levels 
 Serum was collected from mice at 13 to 15 weeks by cardiac puncture, and testosterone 
(T) and luteinizing hormone (LH) levels were determined by radioimmunoassay (RIA) and 
sandwich assay, respectively, by the University of Virginia Center for Research in Reproduction 
Ligand Assay and Analysis Core Facility. The sensitivities of the testosterone RIA and LH assay 
were 10ng/dL and 0.07ng/dL, respectively. 
 
3.5.8 Exercise studies 
 To analyze exercise capacity, a protocol for treadmill running was used as previously 
described [184]. First, mice underwent 2 days of training on an Exer3/6 treadmill (Columbus 
Instruments), with day 1 consisting of five minutes of running at 8 meters/minute, and day 2 
consisting of five minutes of running at 8 meters/minute followed by five minutes at 10 
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meters/minute. On day 3, mice ran using a graded protocol consisting of 10 meters/min for 40 
minutes, then increasing speed by increments of 1 meter/minute every 10 minutes for a total of 
30 minutes, and followed by increasing speed by increments of 1 meter/minute every 5 minutes 
until mice were exhausted. Exhaustion was defined as mice making no attempt to exercise for 5 
seconds. Assessment of endurance in castrated AR113Q males was performed after orchiectomy 
at 6 weeks of age as previously described [101]. Briefly, following anesthetization with 
isoflurane, the pelvic area was shaved and opened bilaterally with 1-cm incisions to reveal testes 
for removal, then closed with suture material.  The University of Michigan Committee on Use 
and Care of Animals approved all procedures involving mice in compliance with the NIH 
Guidelines for the Care and Use of Experimental Animals.  
 
3.5.11 Immunofluorescence analysis 
 PC12 cells were washed in PBS and fixed in 4% paraformaldehyde for 30 minutes at 
room temperature. For quadriceps and soleus muscles, cryosections were prepared using a 
Cryocut 1800 cryostat (Leica) at 10µm. Staining was performed using the indicated antibodies, 
mounted using Vectashield medium (Vector Laboratories), and sealed with nail polish. To 
distinguish between Type I and Type II fibers, FITC-conjugated donkey anti-mouse IgM was 
used against A4.840, and AlexaFluor 555 anti-mouse IgG was used against Ab-2. Fluorescence 
images were acquired using a Zeiss Axio Imager microscope. To calculate percent AR 
aggregation, AR positive nuclear puncta were manually counted and divided by the total number 
of nuclei as quantified by ImageJ (NIH). To calculate fiber type size, the cross-sectional area of 
each fiber within a 40X field was quantified in triplicate using ImageJ, and fiber type was 
discriminated by antibody stain.  
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3.5.12 Gene expression analysis 
 Total RNA was extracted from PC12 cells and from testis, quadriceps and soleus muscles 
from AR knock-in mice with Trizol (Sigma). The RNA samples were then reverse transcribed 
with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to 
manufacturer’s recommendations. Quantitative PCR was carried out using FastStart TaqMan 
Probe Master Mix (Roche) on software supplied with a 7500 Real-Time PCR SDS System 
(Applied Biosystems) and using gene-specific primers with FAM-labeled probes from Applied 
Biosystems (Mouse: Ar, Mm00442688_m1; Chrna1, Mm00431627_m1; Hsd3b1, 
Mm00476184_g1; Myod1, Mm00499518_m1; Myog, Mm00446194_m1. Rat: Baiap2, 
Rn00589411_m1; Chst1, Rn01484520_m1; Ppard, Rn00565707_m1). Relative expression levels 
were calculated by normalizing to the expression of 18S rRNA. For GeneChip microarray 
analysis, cDNA samples from PC12 cells were applied to an Affymatrix Mouse Gene ST 2.1 
Plate by the University of Michigan MicroArray Core. Probe data were inspected for quality 
control by signal density distribution and normalized unscaled standard error estimates. Relative 
expression values were calculated using a robust multi-array average (RMA) with oligo and 
limma packages of bioconductor implemented in the R statistical environment, and p-values 
were adjusted for multiple comparisons using false discovery rate (FDR) as described previously 
[287-290]. Expression values were also inspected for quality control by principal components 
analysis. Genes were considered significantly responsive to androgen if they demonstrated a 1.5-
fold or greater activation or repression in the R1881-treated samples compared to controls and an 
adjusted p-value of 0.05 or less. Genes selected in this manner and relevant information 
(probeset ID, statistics, expression values, gene name, symbol, and links to online databases) 
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were output into Excel for ranking by fold change values and determining the numbers used for 
Venn diagrams. All images were constructed in Photoshop (Adobe).  
 
3.5.13 Statistics 
To determine statistical significance, data sets were analyzed using unpaired two-tailed 
Student’s t-test, ANOVA with Newman Keuls multiple comparison test, or Mantel-Cox log-rank 
test in Prism 6 (GraphPad). Differences between means were defined as significant if p<0.05. 
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Chapter 4 
 
Conclusion 
 
4.1 SBMA and autophagy 
 
4.1.1 The polyQ androgen receptor and autophagic degradation  
Autophagy is a highly conserved catabolic process and essential mechanism of protein 
quality control, and targeting autophagy is postulated to promote clearance of protein aggregates 
responsible for neurodegenerative disease [220]. However, the manner in which manipulation of 
the autophagic pathway affects SBMA is controversial. Previous work establishes that the 
principal site of toxic action for the expanded polyQ AR is the nucleus, and nuclear localization 
of the mutant protein is both an essential step in pathogenesis and prevents efficient degradation 
of the AR by autophagy [98]. Clearance of nuclear-localized polyQ AR is achieved primarily by 
chaperone-dependent ubiquitination and proteasomal degradation [74, 291]. However, 
alternative evidence demonstrates a role for autophagic degradation of the polyQ AR in cell 
culture models that overexpress the mutant protein [185, 292]. Interestingly, enhanced 
expression of p62 ameliorates the disease phenotype of SBMA AR97Q transgenic mice, in part 
by sequestering the polyQ AR into intranuclear aggregates [292]. While these latter studies 
suggest that autophagy may contribute to clearance of the polyQ AR in some model systems, 
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these beneficial effects may be relatively small compared with detrimental consequences of 
enhanced autophagy in tissues affected by SBMA. Although the findings derived from the 
AR97Q mice are suggestive of essential involvement of autophagy in AR proteostasis, it is still 
unclear if these discrepant implications of autophagy are reflective of differences in AR 
expression levels between AR97Q mice and AR113Q knock-in mice. Additional studies 
addressing this unresolved issue include assessing autophagy in relation to levels of AR 
expression and biological context in alternative cell and animal models of SBMA. 
 
4.1.2 Targeting autophagic regulation in SBMA 
 Directing therapeutic strategies against regulatory mechanisms of autophagy, especially 
TFEB, may alleviate much of the dysregulation occurring in SBMA and provide informative 
routes for reducing atrophy in SBMA and other myopathies. Although our data implicate TFEB 
in coordinating elevated autophagy concomitant with expression of polyQ AR in every system 
we examined, the extent to which TFEB represents the primary mediator of upregulated 
autophagy in SBMA or exists downstream of more determinative mechanisms requires 
additional characterization. It would be of interest to modulate TFEB function and expression to 
assess effects on autophagy induction and SBMA phenotype in our model systems. One potential 
way of testing the necessity of TFEB would involve using an adeno-associated viral vector 
expressing HA-tagged TCFEB [178] to transduce wild type mouse muscle and assess the degree 
to which SBMA-like autophagy is recapitulated, or to transduce AR113Q muscle to determine 
the extent of autophagic exacerbation. Furthermore, although homozygous TCFEB mutant mice 
are embryonically lethal [293], heterozygotes are viable and may provide an alternative path for 
probing transcription-dependent changes of autophagy-related genes in SBMA. 
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 Abnormal interactions between TFEB and polyQ AR may underlie pathologic nuclear 
localization akin to the sequestration of other transcription factors trapped in polyQ AR 
inclusions. However, many of those interactions are facilitated by polyglutamine tracts contained 
in those interactors but absent in TFEB. Alternatively, our studies support the notion that TFEB 
localization is primarily a function of regulatory control by phosphorylation events. Concomitant 
with increased TFEB activity, we identified diminished mTOR pathway activity, which is an 
established inhibitory mechanism of regulating TFEB [181-183]. These findings, together with 
the lack of candidate structural or biochemical features conducive for direct polyQ AR-TFEB 
interactions, suggest regulatory derangements upstream of mTOR that are incited by the polyQ 
AR. These upstream mechanisms of inducing autophagy are more well-characterized than TFEB, 
and small molecules that target these molecular entities to block autophagy and the tools for 
identifying them are already in development, though still relatively nascent [294-297]. Promising 
candidate compounds could be administered in our AR113Q male mice at ages preceding 
puberty to interrupt the onset of pathogenesis and determine the degree of autophagy inhibition 
in relation to disease phenotype. Regardless of therapeutic paradigm, caution must be exercised 
in designing agents for inhibiting autophagy, since potential consequences include oncogenesis 
and exacerbation of neurodegenerative sequelae [240, 298, 299].  
It is noteworthy that changes in autophagy demonstrated in model systems of SBMA are 
increased further through physiologic stimuli including starvation and exercise but abrogated by 
Beclin-1 haploinsufficiency [152]. Taken together, these observations suggest that autophagy is 
additionally stimulated in SBMA in part through the Beclin-1 initiation complex, and that 
designing molecular interventions against this machinery would prove beneficial for therapeutic 
purposes. In consideration of this strategy, further biochemical characterization of AR113Q mice 
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that are Beclin-1 haploinsufficient is warranted. In particular, it will be necessary to confirm if 
the decrement in autophagy documented in Beclin-1+/- mice occurs independent from TFEB 
activity. Another consideration within this mechanistic framework is exploiting the effect of 
BCL-2-mediated inhibition of Beclin-1 for SBMA. Knock-in mice harboring the BCL-2 AAA 
mutation disrupt phosphorylation-dependent dissociation of BCL-2 from Beclin-1 and display 
reductions in exercise endurance [184]. Although this cross would be predicted to yield an 
amelioration of the SBMA phenotype by inhibiting autophagy in a mechanism alternative to but 
parallel with Beclin-1 haploinsufficiency, the indication of compromised muscle function in 
phosho-deficient BCL-2 mice may worsen SBMA. Since AR113Q mice demonstrate enhanced 
autophagy in response to a BCL2-dependent mechanism via exercise (Fig. 2.5), further 
examination into genetic modulation of the autophagic pathway is warranted to inform the utility 
of targeting Beclin-1/BCL-2. 
 
4.1.3  Reexamining protein quality control in SBMA  
  Although we have uncovered novel and intriguing aspects of proteostasis in SBMA, 
further details concerning the involvement of autophagy in SBMA remain undefined. For 
instance, the instigatory insults engendered by the polyQ AR and leading to autophagic induction 
through mTOR/TFEB are as yet unidentified. One potential route of determining the etiology of 
upregulated autophagy is testing whether the alterations documented in this study constitute a 
compensatory mechanism in response to pathogenic insults introduced by the polyQ AR. For 
example, impairment of the UPS in SBMA could represent one such insult and is evidenced by 
aberrant sequestration of UPS components in polyQ AR inclusions and depressed UPS activity 
associated with polyQ AR expression [39, 170, 186]. Given that toxicity stemming from UPS 
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impairment is exacerbated by genetic inhibition of autophagy [170], the dysregulated activation 
of autophagy documented in chapter 2 may represent a proteostatic response to the initial UPS 
insult. However, in light of the variability in decompensated UPS activity across multiple model 
systems of SBMA [39, 149, 185], the extent to which protein quality control compensation 
incites mechanisms essential for pathogenesis is incompletely defined, and further investigation 
is required. 
 Our identification of an enhanced autophagic response to exercise on an acute timescale, 
and the consequent increase in protein degradation within exercised SBMA muscle, have 
important ramifications for determining the usefulness of short- and long-term exercise therapy 
in SBMA, not only in current (Trial Number 11-N-0171; NCT01369901) and future clinical 
trials of exercise but also in accounting for the equivocal benefits of exercise seen thus far in 
patients [165, 166]. Since our data are indicative of an elevation of autophagic responsiveness to 
exercise in SBMA, the putative benefits of exercise intervention are questionable and may be 
overshadowed by inordinate activation of protein degradative mechanisms. One such study to 
address this point would be to assess the effects of physical exertion on disease in a chronic 
exercise trial of our AR113Q knock-in mice, including measures of the degradation activity of 
autophagy in relation to muscle proteostasis, function, and atrophy. This pilot experiment would 
prove supplemental to the current exercise trials enrolling human patients and informative of 
autophagic and myopathic measures at the molecular, histologic, and organismal level 
underlying patient performance.  
 
4.2 SBMA and SUMO 
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4.2.1 AR113Q-KRKR mice and SBMA pathogenesis 
SUMO modification is a ubiquitous posttranslational modification that modulates 
substrate function to regulate multiple cellular processes, including activity of the AR. In chapter 
3, our data analyze the effect of SUMOylation on the polyQ AR in a novel mouse model of 
SBMA. We generated a new knock-in mouse model abrogating SUMO modification of the 
polyQ AR by mutating lysine residues in two consensus SUMO acceptor sites to arginine. Our 
strategy allows for multiple measures of AR toxicity in tissues selectively vulnerable in SBMA 
and enables analysis of altering AR function in pathogenicity. In comparison to disease 
phenotype in AR113Q mice, we find that disruption of AR113Q SUMOylation does not 
significantly modify aspects of endocrine compromise. These findings are significant because 
they establish that loss of AR function is not sufficient to explain compromise in HPG axis 
tissues in SBMA, nor does partial recovery of AR function, as evident in our microarray data of 
AR112Q-KRKR (Fig. 3.2B-D), correct these endocrine alterations. Rather, our novel knock-in 
model suggests that polyQ AR toxicity contributes to endocrine tissue pathology, independent of 
the level of trophic support provided by the degree of AR function. These results have major 
implications for reassessing the relative contributions of polyQ AR loss of funcion and toxic gain 
of function to SBMA pathogenesis. 
Although we detected no substantial differences in several measures of AR toxicity and 
aggregation, we intriguingly observed a significant recovery of exercise capacity in SBMA mice 
expressing non-SUMOylatable polyQ AR. This rescue persisted even into old age, despite 
decrements in exercise fitness across all genotypes. Moreover, the exercise endurance 
documented in AR113Q-KRKR mice occurs despite comparable levels of bulk muscle atrophy 
and pathology and despite the KRKR variant of polyQ AR containing a significantly greater 
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number of CAG repeats on average than the SUMOylatable AR113Q (92.3±0.3 vs. 111.2±0.2, 
p<0.0001 by Student’s t-test). Additionally, and perhaps most intriguingly, disruption of polyQ 
AR SUMOylation produces an almost complete rescue of SBMA mortality. Together, our results 
suggest that expanded polyQ tracts are permissive and sufficient for toxicity, as indicated by 
unaltered aspects of disease phenotype, but critical modifiers of muscle physiology and survival 
in SBMA are repressed by SUMO modification of the polyQ AR.  
Our studies identified unexpected beneficial effects of the ligand-activated polyQ AR, as 
abrogating SUMOylation both enhances the receptor’s native function in a gene-specific manner 
and ameliorates the disease phenotype. The ligand-dependent trophic effects on exercise capacity 
and survival are striking, and distinct from the proteotoxicity mediated by ligand-stimulated 
unfolding that drives SBMA pathogenesis. The mechanism by which the KRKR mutant exerts 
these trophic effects will require additional study. Promising candidates for further investigation 
include genes that we identified as ligand-responsive to AR10Q and AR112-KRKR but not 
AR112Q. This list includes transforming growth factor-3 (TGF-3), CCAAT/enhancer binding 
protein- -  documented to be androgen-
responsive or implicated in positively regulating muscle physiology, mitochondrial homeostasis, 
nutrient metabolism, and exercise tolerance [111, 154, 300-314]. Our findings establish that 
enhancing the anabolic effects of AR on muscle, and perhaps other target tissues, in SBMA mice 
rescues the disease phenotype, and suggest that the SUMOylation pathway may provide new 
targets for therapeutic intervention. 
 
4.2.2 Implications of SUMO-dependent control of AR function 
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Repression of transactivation function is a major regulatory role of SUMOylation for 
steroid hormone receptors, including the AR. Disruption of AR SUMOylation induces 
dissociation of AR from the nucleoplasm and promotes association with chromatin, thereby 
potentiating AR transactivation [63, 217, 218, 271]. Given the partial loss of AR function and 
androgen insensitivity phenotype in SBMA, it follows that several aspects of disease 
development may be affected by interrupting SUMO modification of the AR.  
Despite the prevailing notion that loss of function is integral to SBMA, recent work 
nevertheless implicates native AR function as indispensible for pathogenesis, specifically 
intramolecular interactions mediated by activation function surface 2 (AF-2) [89]. Given that our 
microarray analysis confirms that KRKR mutations in AR significantly increase androgen-
dependent transactivation (Fig. 3.2), we would therefore predict an exacerbation of disease 
phenotype under the model of AR function orchestrating toxicity. In contrast, not only do we 
observe that a majority of disease aspects remain unchanged in mice expressing non-
SUMOylatable AR113Q, but several are ameliorated (Fig. 3.5 and 3.6). Additionally, our 
exercise rescue was androgen-dependent, suggesting that AR function is essential for reversing, 
not causing, aspects of toxicity (Fig. 3.5C). Altogether, our results argue against the necessity of 
native AR function in pathogenesis. 
These results raise several important questions to account for the discrepancies observed 
in probing function-dependent aspects of AR-mediated toxicity in vivo. To address 
characteristics of AR function unaccounted for by our studies, a key addition to our analyses 
would be investigating the activity of non-SUMOylatable, unexpanded Q-tract AR and 
introducing KRKR mutations in an AR21Q knock-in line of mice. We have already generated an 
AR10Q-KRKR PC12 cell line, and critical insights would be gleaned from additional microarray 
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analysis of changes in AR transactivation in these cells compared to expression activity under 
AR112Q-KRKR and AR with AF-2 mutations. Our results also indicate that phenotypic rescue 
of SBMA in AR113Q-KRKR mice warrant development of therapies targeting SUMO 
modification of the polyQ receptor, particularly by developing agonists of the deSUMOylating 
protease specific for AR, SENP1 [66, 68]. In conclusion, our modeling of disrupted 
SUMOylation in vivo dispels the conclusion that inherent function of the AR is pathogenic, and 
provides a valuable tool for studying polyQ AR physiology discretely from polyQ AR toxicity. 
 
4.2.3 Insights regarding exercise physiology in SBMA 
 The rescue of exercise capacity in our novel mouse model requires further study to 
delineate what aspects of muscle pathophysiology in SBMA are ameliorated by abrogating 
polyQ AR SUMOylation. One possible interpretation of the differences observed in exercise 
endurance is improved cardiovascular function. However, the lack of evidence supporting 
cardiac-related deficits in human SBMA patients renders this explanation unlikely [315]. In 
contrast, our complementary analyses of skeletal muscle revealed that, although bulk atrophy is 
documented in AR113Q-KRKR mice, we uncovered selective resistance to atrophy in Type I 
fibers (Fig. 6F).  
Type I muscle fibers are primarily reliant on oxidative phosphorylation for energy 
metabolism and are major factors in augmenting exercise endurance [316]. One candidate 
mediator of Type I fiber rescue in AR113Q-KRKR mice is PPAR, a primary determinant of 
Type I phenotype development and type switching in skeletal muscle that is androgen-responsive 
[317-320]. To confirm the relationship of PPAR and Type I physiology to the exercise 
phenotype that we found in SBMA mice, future studies will need to assess the influence of 
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PPAR and its transcriptional programming in the context of SBMA and other cases of 
neuromuscular dysfunction. Additional future studies of cell and animal models of SBMA 
treated with PPAR agonists, including telmisartan, HFCS-55, and GW derivatives, are also 
required to further delineate the extent to which PPAR activity rescues SBMA [321-323]. The 
apparent rescue of Type I fiber atrophy may account for the improved exercise fitness in SBMA 
mice, and our AR113Q-KRKR mice establish the trophic effect of improving AR function in 
Type I muscle.  
 
4.3 Concluding remarks 
Functioning mechanisms of protein quality control and regulation by posttranslational 
modifications are essential aspects of proteostasis in protecting normal cellular processes from 
pathogenic perturbations. The subjects of this dissertation illustrate key features and profound 
effects of manipulating these mechanisms to enhance or diminish different facets of disease 
pathogenesis. Although prevailing studies advocate inducing autophagy to combat 
neurodegenerative disease, we argue a significant counterexample in which excessive autophagy 
may be maladaptive. Similarly, while several studies highlight ameliorative effects of 
SUMOylation on mutant protein pathogenicity, we demonstrate a novel and profound restorative 
effect of antagonizing SUMOylation on disease. The physiological rescues we document in 
studying AR SUMOylation are due in no small part to alterations in transactivational 
compromise, an additional component of pathophysiology unique to SBMA and distinct from 
other neurodegenerative disorders. Although the search for curative interventions in 
neurodegeneration is ongoing, our research identifies and establishes novel therapeutic targets 
 83 
and opens new lines of investigation into further understanding cellular and molecular modifiers 
of SBMA pathogenesis. 
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